




BRIC
a DBT Organization



NCCS
NATIONAL CENTRE FOR CELL SCIENCE

National Centre for Cell Science

Annual Report

2024-25

Table of Contents

| Section | Item | Pg. No. |
|--|--|------------------|
| Part A | | |
| | Overview | 1 |
| Part B (Nov 2024 – Oct 2025) | | |
| | Mandate | 2 |
| | Research Focus | 2 |
| | Thematic Areas | 2 |
| | Key Research Highlights | 3 |
| | Publications, Patents & Technologies | 7 |
| | Significant Collaborations | 8 |
| | New Extramural Projects | 10 |
| | Ongoing Extramural Projects | 11 |
| | Awards, Distinctions and Fellowships Received by Faculty | 14 |
| | Start-ups/ Entrepreneurship-related Activities | 15 |
| | Major Events & Outreach Activities | 16 |
| | Research Infrastructure | 22 |
| | Services Offered | 24 |
| | RTIs & Grievances | 24 |
| Annexures | | |
| Publications (Nov 2024 – Oct 2025) | Publications List | PL-1 to PL-12 |
| Budget & Finance (FY 2024–25) | Audited Statements of Accounts | AC-1 to AC-39 |

Part A: Overview

The National Centre for Cell Science (BRIC-NCCS), located in Pune, is a premium research organization in India that has been contributing to the nation's excellence in biomedical science via cutting-edge multidisciplinary research in cell biology. Aligned with global sustainable development goals, our research is especially focused on addressing national needs related to human health. The objective of our research is to understand the nuances of the cellular and molecular underpinnings of various diseases and disorders. This will serve to identify potential targets to improve diagnostic methods and treatment regimen, leading to improved disease management.

BRIC-NCCS offers many services that facilitate high quality research across India. We serve as a national cell repository for animal cell cultures, which are provided to researchers from academia and industry. Therefore, a significant proportion of cell biology research in India relies on our repository, and is also supported by our routinely provided training in cell culture technology. BRIC-NCCS has served and continues to serve as a national and international depository for microorganisms. Several other services are also offered by our central facilities with state-of-the-art research tools and competent technical staff.

BRIC- NCCS contributes to capacity building of the nation through several teaching, training & outreach activities that benefit students, researchers & academicians, as well as the public at large. These include the Ph.D. program, project and summer research training, internships, workshops, support provided to postdoctoral researchers, and public engagement initiatives.

1. Mandate:

BRIC-NCCS was established with a mandate of three main objectives as listed below:


- i. To serve as a national cell repository.
- ii. Research in cell biology.
- iii. Human resource development.

2. Research focus:

The research at BRIC-NCCS is aimed at addressing challenging questions related to cancer, metabolic and neurological disorders, infection and immunity, stem cells and regenerative biology, and the role of the human microbiome in health and disease. This research encompasses diverse interdisciplinary approaches using cutting-edge technologies in cell biology, structural biology, bioinformatics, systems biology, proteomics, metabolomics, and metagenomics.

3. Thematic areas being dealt with in the institute:

Twenty-five research groups at BRIC-NCCS are engaged in interdisciplinary research across one or more of the following areas:



4. Key research highlights

Investigations done at BRIC-NCCS on a severe form of ovarian cancer revealed how cancer stem cells can survive under stress. Cells deprived of nutrients and growth signals were found to adapt by changing their energy production methods. Specifically, they switch from relying on sugar breakdown to using fats through a process called oxidative phosphorylation in the mitochondria—the cell's powerhouses. These changes are linked to the cancer cells' ability to behave like stem cells, which can renew and sustain tumor growth. This study suggests that targeting these mitochondrial functions could help eliminate cancer stem cells, thus potentially preventing tumor recurrence and improving treatment outcomes. These findings highlight a new approach to attack the resilience of ovarian cancer by disrupting its energy supply mechanisms. These studies that were published in **Cell Death and Disease** (Oct. 2025).




Figure: Mitochondria-associated functions that support cancer stemness in serum-free media identified in ovarian cancer

Source of the graphical abstract – DOI: 10.1038/s41419-025-07987-1

It is known that the immune system plays a role in aggravating bone loss in osteoporosis, but the underlying mechanisms were unclear. Scientists at BRIC-NCCS investigated how the complement component C3 of the immune system regulates the

differentiation of osteoblasts (bone-forming cells) and osteoclasts (cells responsible for bone resorption) in the mouse model. A deficiency of C3 was found to reduce the differentiation of osteoclasts, and the decrease in osteoclast function led to increased bone health, including parameters associated with better strength. This study provides valuable insights into how the bone-immune axis contributes to the regulation of bone health, and suggests potential C3-associated therapeutic avenues for the management of bone disorders. This research was published in **The Journal of Immunology** (Aug. 2025), and featured online in the News & Views section of the American Association of Immunologists.




Figure: BRIC-NCCS research revealing the role played by complement C3 in bone health was featured by the American Association of Immunologists.

Source of the graphical abstract – DOI: 10.1093/jimmun/vkaf180

The protein, clathrin, mediates endocytosis (movement & distribution of molecules between membrane-bound cellular components), by coating vesicles with a structure composed of clathrin heavy chain (CHC) and clathrin light chain (CLC) molecules. Research at BRIC-NCCS has revealed a novel role played by the light chain, CLCa, in coordinating cell communication and structure in embryonic stem cells, highlighting the importance of CLCs in embryonic development. This research was published in **Life Science Alliance** (May 2025).




Figure: CLCa mediates a novel cross-talk between Wnt secretion and actin organization.

Source of the graphical abstract – DOI: 10.26508/lsa.202402962

Protein complexes known as processing bodies (PBs) play an important role in controlling the stability and translation of messenger RNA (mRNA), which is essential for protein production in cells. The relative localization of PBs with respect to the other organelles within the cell was unclear. Research done at BRIC-NCCS showed that a subset of PBs resides at the ER-mitochondria contact sites (ERMCSSs), and that disruption of ERMCSSs lead to an autophagy-dependent loss of PBs, thereby identifying a potential link between ERMCSSs and the post-transcriptional regulation of gene expression via PBs. These studies have thus revealed a novel process via which cells regulate important processes like gene expression and protein production by maintaining specific cellular structures. Understanding this relationship can help us discover how cellular stress conditions or diseases might disrupt these processes, potentially leading to new strategies for treatment or prevention. This research was published in the **Journal of Cell Science** (March 2025). Nikhil More, the first author and a PhD student at BRIC-NCCS, was featured in the 'First Person' section of this journal, which covers interviews of authors of selected papers.




Figure: Model depicting how ERMCS maintain PBs.

Source – DOI: 10.1242/jcs.263652

Research at BRIC-NCCS has revealed how HIV manipulates a host microRNA, miR-197-3p, which helps new virus particles become more infectious. It increases this miRNA by suppressing a specific human protein, DDX52, which normally acts to reduce infectivity. By lowering DDX52 levels, the virus ensures that its accessory protein Vif stays stable and active. Vif then disables a host defense enzyme (APOBEC3G) that would otherwise damage the virus's genetic material. Understanding these molecular interactions provide potential new therapeutic targets to reduce HIV infectivity. These findings were published in the **Journal of Biological Chemistry** (Feb. 2025).




Figure: Schematic representation of how miR-197-3p regulates HIV-1 progeny virion infectivity

5. Publications, Patents & Technologies

Publications: Please see the annexure for list of publications.

Patents Granted:

| No. | Patent Details |
|-----|---|
| 1 | Title: A Nanohybrid, Its Method of Preparation and Use Applicants: National Centre for Cell Science, IIT -Bombay Date of Grant: 10.12. 2024 Patent Grant No.: 556015 - INDIA |
| 2 | Title: Antiviral Drug Compounds and Composition Thereof. Applicant: National Centre for Cell Science Date of Grant: 02.01.2025 Patent Grant No.: 3793561 - EP (Germany, France, UK) |
| 3 | Title: A Novel Anti-Cancer Combination and a Method of Therapy Using The Combination. Applicant: National Centre for Cell Science Date of Grant: 08.01.2025 Patent Grant No.: 3846789 - EP (Germany, France, UK) |
| 4 | Title: A Novel Chimeric Protein Kinase C as an Immunomodulator. Applicant: National Centre for Cell Science Date of Grant: 20.05.2025 Patent Grant No.: BR 112020016654-5- Brazil |

Patents filed: Nil

Technologies Developed:

| No. | Technology |
|-----|--|
| 1 | A Nanohybrid, Its Method of Preparation and Use Patent granted in India |
| 2 | Antiviral Drug Compounds and Composition Thereof Patent granted by EPO (Germany, France, UK) |

| | |
|----------|---|
| 3 | A Novel Anti-Cancer Combination and a Method of Therapy Using the Combination Patent granted by EPO (Germany, France, UK) |
| 4 | A Novel Chimeric Protein Kinase C as an Immunomodulator Patent granted in Brazil |

Technologies transferred: Nil

6. Significant Collaborations

International Collaborators

- **BIOSANTEXC Programme collaborator:** Dr. Kiran Padmanabhan, Institute of Genomics Functions, Lyon, France
- Dr. Florence Besse, Institut Biologie-Valrose (iBV), Nice, France
- Dr. Aaron Turkewitz, The University of Chicago, USA

National Collaborators

- **Pune Biotech Cluster: 'Model Organism to Human Disease'**
 - Prof. Sunil S. Bhagwat, Director, IISER, Pune
- **DBT-Celiac Consortium Project collaborators:**
 - **AIIMS, New Delhi:** Dr. Govind Kumar Makharia, Dr. Prasenjit Das, Dr. Vineet Ahuja, Dr. Rohan Malik, Dr. Mani Kalaivani
 - **IIT Delhi:** Dr. Arjun Ray, Dr. Tarini Shankar Ghosh
 - **IGIB, New Delhi:** Dr. Shantanu Sengupta, Dr. Swarnendu Bag
 - **Institute of Medical Education and Research, Chandigarh:** Prof. Saroj Sinha, Dr. Jayanta Samanta
 - **IGIB New Delhi:** Dr. Shantanu Sengupta, Dr. Swarnendu Bag
 - **Sardar Patel Medical College, Bikaner:** Prof. Sushil Falodia, Dr. Ashish Joshi
 - **AIIMS Rishikesh:** Dr. Alka Kumari
 - **RCB, Faridabad:** Dr. Chittur Srikanth
- **NIBMG, Kalyani:** Dr. Kartiki Desai
- **Deenanath Mangeshkar Hospital, Pune:** Dr. Anup Tamhankar
- **CSIR-CCMB:** Dr. Janesh Kumar

- **BRIC-NII, New Delhi:** Dr. Bichitra Biswal
- **NISER, Bhubaneswar:** Dr. Abdur Rahman
- **RCB, Faridabad:** Dr. Karthigeyan Dhanasekaran
- **Guru Ghasidas Vishwavidyalaya, Bilaspur:** Dr. Santosh Kumar
- **NCPOR Goa:** Dr. K. P. Krishnan
- **Centre for Marine Living Resources and Ecology, Cochin:** Dr. N. Saravana
- **CDRI, Lucknow:** Dr. Narendra Tadigoppula
- **Pondicherry University, Pondicherry:** Dr. S. Venu
- **NIOT, Velacherry:** Dr. G. Dharani
- **King George Medical University, Lucknow:** Dr. Satyendra Kumar Singh
- **Saroj Gupta Cancer Centre & Research Institute, West Bengal:** Dr. Somsubhra Nath
- **MUHS, Nashik:** Dr. Sourav Sen
- **IBSD Imphal:** Dr. Pulok Kumar Mukherjee
- **ICGEB, New Delhi:** Dr. Ranjan Nanda
- **IIT Bhubaneswar:** Prof. Shantanu Pal
- **KIIT Bhubaneswar:** Dr. Vishakha Raina
- **School of Health Sciences, S. P. Pune University, Pune:** Dr Girish Tillu
- **SKAN Research Trust:** Dr. Yogesh Shouche
- **AFMC, Pune:** Dr. TVSVGK Tilak, Dr. Saurabh Bobdey, Col. Uday Yanamandra
- **AIIMS, Delhi:** Dr. Sachin Kumar, Dr. Surendra Kumar Sharawat, Dr. Prabhat Singh Malik, Dr. Sunil Kumar, Dr. Prasenjit Das, Dr. Vineet Ahuja, Dr. Rohan Malik, Dr. Mani Kalaivani
- **Annamalai University, Parangipettai:** Dr. A. Gopalakrishnan, Dr. S.T. Somasudaram
- **BRIC-RGCB, Thiruvananthapuram:** Dr. Ananthalaxmy Sundaraman, Dr. A. Sundaraman
- **Cochin University of Science and Technology, Cochin:** Dr. T. P. Sajeevan, Dr. Rosamma Philip
- **CSIR-CSMCRI Bhavnagar:** Dr. Soumya Haldar, Dr. Pramod B. Shinde, Dr. Anil Kumar M
- **CSIR-IICT, Hyderabad:** Dr. G. Jithender Reddy, Dr. Ramesh Ummanni
- **Goa University, Goa:** Dr. Savita Kerkar, Dr. Sanjeev C. Ghadi, Prof. S.G. Tilve
- **IGIB New Delhi:** Dr. Shantanu Sengupta, Dr. Swarnendu Bag

- **IISER Berhampur:** Dr. Vivek Tiwari, Dr. Vishwas Chavan
- **IISER Bhopal:** Dr. Vishal Rai, Dr. Ram Kumar Mishra, Dr. Sanjeev Shukla, Dr. Debasis Nayak
- **IISER, Pune:** Dr. Girish Ratnaparkhi, Dr. Sarita Puri
- **IIT Bombay:** Prof. Pramod Wangikar, Dr. Yogendra Shastri
- **Institute of Life Sciences, Bhubaneswar:** Dr. Rajeeb Swain, Dr. Debasis Dash
- **Institute of Medical Education and Research, Chandigarh:** Prof. Saroj Sinha, Dr. Jayanta Samanta
- **NIMHANS, Bengaluru:** Dr. Gautam Udupi, Dr. Biju Vishwanath, Prof. Chetan GK, Dr. Sivaraman Padavattan
- **Periyar University, Salem:** Dr. R. Balagurunathan, Dr. S. Venkatesan
- **Punjab University, Chandigarh:** Dr. Ravi Pratap Barnwal, Dr. Bharat Bajaj, Dr. Gurpal Singh
- **Satybhama Institute of Science and Technology, Chennai:** Dr. M. Radhakrishnan, Dr. Wilson Aruni, Dr. D Inbakandan, Dr. L Stanley Abraham
- **University of Hyderabad, Telangana:** Prof. Sharmistha Banerjee, Dr. Krishanveni Mishra

7. New Extra Mural Projects

| Sr No | Project |
|-------|--|
| 1 | Investigating the role of Substance P-mediated neuroimmune communication in controlling gut inflammation Funding Agency: DBT |
| 2 | Harnessing the inherent potential of soil microbiome in inducing disease suppressiveness in arable land. Funding Agency: DBT |
| 3 | Bioengineering Research Centre (Microbial Bio-foundry) at NCCS Funding Agency: DBT |

| | |
|---|---|
| 4 | Elucidation of Interaction Mechanisms of TDP-43 and Annexin A11 proteins, and the Pathological Basis of Heteromeric Aggregation in Neurodegenerative diseases. Funding Agency: ANRF |
| 5 | Characterization of structural heterogeneity of human Tau condensates in functional and diseased states. Funding Agency: ANRF |
| 6 | Feathered bioreactors; Leveraging CIRSPR technology to produce human monoclonal antibodies in chimeric chicken eggs. Funding Agency: SERB/ANRF |

8. Ongoing Extra Mural Projects

| Sr No | Project |
|-----------------------------------|--|
| Currently Ongoing Projects | |
| 1 | Establishment of GMP-Compliant National Repository for banking, safe deposit and supply of characterized mammalian cells for use in biopharma. Funding Agency: BIRAC |
| 2 | Precision antibodies engineering centre (PACE). Funding Agency: SERB |
| 3 | Understanding the functions of Annulate Lamellae, an underexplored cell organelle. Funding Agency: SERB |
| 4 | A novel function for a conserved bio-amine in long-term memory and RNA granule remodeling-No. 6503-E. Funding Agency: IFCPAR |
| 5 | Characterization of the effect of pathogenic Cltc variants in early development. Funding Agency: DBT |
| 6 | To develop therapeutic leads to counter PD-L1 mediated suppression of immune system in cancer microenvironment. Funding Agency: ICMR |
| 7 | Identification and validation of neoantigens in a syngenic mouse model of ovarian cancer. Funding Agency: ICMR |
| 8 | Characterization of Pseudogene-like CTs in Ovarian Cancer. Funding Agency: DBT |
| 9 | Generation of novel high-affinity human monoclonal antibody cocktail against Rabies virus for efficacious post-exposure prophylaxis. Funding Agency: Sree Padmavathy Venkateswara Foundation |

| | |
|----|--|
| 10 | Understanding the molecular mechanism of biogenesis of lysosome-related organelles using the <i>Tetrahymena thermophila</i> model system. Funding Agency: DBT/Wellcome Trust India Alliance |
| 11 | Understanding the role of specific serotonin receptor signaling in modulating the antigen-specific immunity to control tumor growth. Funding Agency: SERB |
| 12 | Establishment of A Pune Biotech Cluster, "Model Organism to Human Disease" Funding Agency: DBT |
| 13 | VAPB at membrane contact sites: ALS-FTD at the crossroads of ER stress, proteostasis, lipid homeostasis and inflammation. Funding Agency: Pratiksha Trust |
| 14 | Understanding the virus-nuclear pore complex crosstalk using computational and structural biological approaches. Funding Agency: DBT |
| 15 | Functional implications of evolutionarily conserved motifs in compliment factor H-an alternative complement pathway regulator linked to multiple human diseases. Funding Agency: DBT (M K Bhan Fellowship) |
| 16 | Identifying the role of host F-box proteins, a component of E3 ubiquitin ligase complex, in HIV-1 pathogenesis and their potential use as therapeutic target against the virus. Funding Agency: SERB |
| 17 | Molecular and Functional studies on LncRNA-guided regulation of replication stress response and genome integrity in mammalian cells. Funding Agency: CSIR |
| 18 | Investigating the role of Clathrin Light Chain in Neural Development and Function. Funding Agency: CSIR |
| 19 | Exploring the Marine Ecosystems for Novel Bioresources with Human Health and Industrial Significance. Funding Agency: Ministry of Earth Sciences |
| 20 | Identifying the neuro-immune pathways that modulate feeding behavior and metabolism in <i>Drosophila</i>. Funding Agency: DBT |
| 21 | Deciphering the molecular mechanism of fluid phase alternative pathway regulation by complement regulatory protein factor H. Funding Agency: ANRF |
| 22 | Investigating the role of Substance P-mediated neuroimmune communication in controlling gut inflammation. Funding Agency: DBT (Tata Innovation Fellowship) |
| 23 | Ayurveda-based botanicals and Alzheimer's disease-AYUSH Center of Excellence, Center for Complementary and Integrative Health School of Health Sciences, SPPU. Funding Agency: Ministry of Ayush |
| 24 | Ayurveda-based botanicals and rheumatoid arthritis-AYUSH Center of Excellence, Center for Complementary and Integrative Health School of Health Sciences, SPPU. Funding Agency: Ministry of Ayush |

| | |
|--|--|
| 25 | Dissecting the <i>Mycobacterium tuberculosis</i> -human protein-protein interactions by using deep learning framework. Funding Agency: DBT (MK Bhan Fellowship) |
| 26 | Investigating the molecular mechanisms of TIA-1-mediated liquid-liquid phase separation and its implication in neurodegenerative disease. Funding Agency: DBT (MK Bhan Fellowship) |
| 27 | Understanding and targeting phase-separated transcriptional biomolecular condensates as oncotherapy. Funding Agency: DST (INSPIRE) |
| 28 | Harnessing the inherent potential of soil microbiome in inducing disease suppressiveness in arable land. Funding Agency: DBT |
| 29 | Bioengineering Research Centre (Microbial Bio-foundry) at NCCS. Funding Agency: DBT |
| 30 | Elucidation of Interaction Mechanisms of TDP-43 and Annexin A11 proteins, and the Pathological Basis of Heteromeric Aggregation in Neurodegenerative diseases. Funding Agency: ANRF |
| 31 | Characterization of structural heterogeneity of human Tau condensates in functional and diseased states. Funding Agency: ANRF |
| 32 | Feathered bioreactors; Leveraging CRISPR technology to produce human monoclonal antibodies in Chimeric chicken eggs. Funding Agency: SERB/ANRF |
| 33 | Influence of obesity-associated factors on immune cells (monocytes and macrophages) as well as on DNA damage response and its implications in cancers. Funding Agency: SERB |
| 34 | JC Bose Fellowship (Dr. Arvind Sahu) Funding Agency: SERB |
| 35 | JC Bose Fellowship (Dr. Shekhar Mande) Funding Agency: SERB |
| Projects completed during the period under review | |
| 36 | Elucidation of the role of long noncoding RNA-Ginir as a biomarker in lung tumorigenesis. Funding Agency: DBT Completed (End Date: 18-08-2025) |
| 37 | Establishment of Center of Excellence for "National Center for Microbial Resource (NCMR)." Funding Agency: DBT Completed (End Date: 31-03-2025) |
| 38 | Bioprospecting of Marine microbial diversity for various products under the Marine Bioresource and Biotechnology Network Programme. Funding Agency: DBT Completed (End Date: 27-03-2025) |
| 39 | Identifying interactors of E-cadherin in embryonic stem cells. Funding Agency: SERB Completed (End Date: 30-12-2024) |
| 40 | Identification and characterization of downstream effector proteins for Gao, the major neural G protein in brain tissue. Funding Agency: DBT Completed (End Date: 19-12-2024) |

| | |
|----|--|
| 41 | Delineation of the major brain G protein, G_o mediated signaling pathway using <i>C. elegans</i> model system. Funding Agency: SERB Completed (End Date: 29-12-2024) |
| 42 | Studying the liquid-liquid phase separation properties associated with a transcriptional co-activator. Funding Agency: SERB Completed (End Date: 20-07-2025) |
| 43 | Structure and function of trans-synaptic complexes mediated by Neurexin, Cerebellin and GluD receptors. Funding Agency: DBT (M K Bhan-Young Researcher Fellowship Programme) Completed (End Date: 10-02-2025) |
| 44 | Clinical role of a pair of novel mutations in BCR-ABL 1 towards therapy switch in imatinib resistant chronic myeloid leukemia. Funding Agency: Lady Tata Fellowship Completed (End Date: 13-12-2024) |
| 45 | System regulatory networks of autophagy proteins in leishmania: Implication towards drug design. Funding Agency: ICMR Completed (End Date: 27-03-2025) |
| 46 | Investigating molecular mechanisms governing the proliferation - differentiation balance in adult stem cells during chronic infections. Funding Agency: DST (INSPIRE) Completed (End Date: 24-07-2025) |
| 47 | DBT Consortium on Celiac Disease. Funding Agency: DBT Completed (End Date: 03-09-2025) |
| 48 | Recognition of RNA structural motifs by bespoke small-molecules to interrogate and alter RNA-RBP interactions associated with phase-separated toxic aggregate formation. Funding Agency: DBT/Wellcome Trust India Alliance Completed (31-03-2025) |
| 49 | Protein Phase Separation: New drug target space for neurological disorders. Funding Agency: DBT Completed (31-3-2025) |

9. Awards, Distinctions and Fellowships Received by Faculty

➤ Dr. Sharmila Bapat:

- The M. G. Deo Oration at the 44th Annual meeting of the Indian Association of Cancer Research (IACR) at Kolkata. 16 January 2025.
- Lifetime Achievement Award for the year 2025 from the Golden Jubilee Biotech Park for Women Society. 08 March 2025.
- Elected as Fellow of the Indian National Science Academy, for her research in Cancer Biology, especially her pioneering work on Cancer Stem Cells associated with high grade Ovarian Cancer.
- Elected as Council Member of the Indian Academy of Sciences, Bengaluru for the triennium 2025–2027.

- Member of the Fellowship Security Committee (FSC) 2025–2028 for Animal Sciences of National Academy of Sciences, India (NASI).
- Appointed as Advisory Committee Member of the Indian Cancer Genome Atlas (ICGA).
- Nominated as member for Local Research Advisory Committee (LRAC) of AFMC, Pune.

➤ **Dr. Jomon Joseph:** Elected as Fellow of the Indian National Science Academy, for his research in cell biology, especially his work on annulate lamellae (AL), a less studied cellular compartment.

➤ **Dr. Girdhari Lal:** Indian National Science Academy (INSA) Associate Fellow 2024.

➤ **Dr. Akanksha Chaturvedi:** The Scientific High Level Visiting Fellowship (SSHN) for 2025.

➤ **Dr. Senthil Kumar Thangaraj:** DBT Ramalingaswami Re-entry Fellowship 2025 (only the Research Grant Component)

➤ **Dr. Radha Chauhan:** BIOSANTEXC travel fellowship (2024-2025) funded by the French Embassy for initiating an Indo-French academic research programme.

➤ **Dr. Nibedita Lenka:** Invited by ICMR to serve as an Expert Member for their Technical Advisory Group (TAG) committee to review and recommend the project proposals for the Centre of Advanced Research (CAR) in the area of maternal health.

➤ **Dr. Santosh Kumar:** Invited as Guest Faculty at the University of Chicago, USA (26 November 2024 - 12 June 2025), with support from the DBT/Wellcome Trust India Alliance Intermediate Fellowship.

10. Start-ups/ Entrepreneurship-related Activities

- **Seminar series: "Biotech for Sustainable Growth: Rendezvous with Leaders from the Industry":** Aimed at creating awareness about entrepreneurship as a career opportunity, and the strategies to address the challenges involved. The faculty and students engaged in extensive conversations with stalwarts from the industry, who gave talks at NCCS, as listed below:

| Speaker | Affiliation | Seminar Date | Talk Title |
|-------------------------------|--|---------------|--|
| Dr. Vilas P. Sinkar | Former Vice President, Unilever Strategic Science, and Head of Unilever R&D, Bengaluru | 07 March 2025 | Career opportunities for PhD students |
| Dr. Umesh Shaligarm | Director, R&D, Serum Institute of India Pvt. Ltd. | 17 April 2025 | Vaccine development |
| Prof. Pramod Wangikar | Professor and Head of the Department, Chemical Engineering, IIT Bombay | 07 April 2025 | Harnessing metabolomics for precision health, bioprocess optimization, and metabolic engineering |
| Dr. Murali Ramachandra | CEO, Aurigene Oncology Limited, Bengaluru | 15 May 2025 | Opportunities for targeting immune checkpoint proteins in cancer therapy using small molecule inhibitors |
| Dr. Amulya K. Panda | Associate Director, Panacea Biotech Ltd. New Delhi | 13 June 2025 | Challenges in translating innovations in biotechnology |

- **Meeting with Members of the Centre for Process Innovation (CPI), UK:**

In association with DBT and the British High Commission in India, BRIC-NCCS hosted talks by Dr. Arun Harish (Chief Strategy Officer) and Mr. Kris Wadrop (Managing Director – Materials) from CPI, UK, and a round table meeting between them and leaders from industries and startups in the biotechnology sector, and with Directors of national research organizations, to fuel conversations aimed at creating a robust biomanufacturing ecosystem aligned with the BioE3 policy. 06 June 2025.

11. Major Events & Outreach Activities

EVENTS

- **ProUPS Satellite Meeting:** Proteostasis and Ubiquitin Proteasome System. 06, 07 February 2025.
- **India/EMBO Lecture Course:** 'RNA-protein complexes: From molecular assembly to physiological functions and disease' (24–28 February 2025)

| | | |
|---|--|---|
|  <p>गांधी विज्ञान केन्द्र, पुणे संस्कृति विभाग</p> | <p>IndiaEMBO Lecture Course</p> <h2>RNA-protein complexes: from molecular assembly to physiological functions and disease</h2> |  <p>गांधी विज्ञान केन्द्र, पुणे संस्कृति विभाग</p> |
| <p>Dr. Florence Besse Institut de Biologie Valrose, France</p> | | <p>Dr. Amitabha Majumdar BRIC-NCCS, India</p> |

- **37th Foundation Day of NCCS (26 August 2025):**

| | |
|---|---|
|  <p>BRIC NCCS गांधी विज्ञान केन्द्र संस्कृति विभाग</p> |  |
| <p>Foundation Day Oration by Dr. Vijay Chauthaiwale: 'Innovation Ecosystem in India'</p> | <p>Panel Discussion: 'BioE3 at One: Green Growth, Good Jobs, Cleaner Future'</p> |

- **Industry-Academia Monthly Seminar Series (March – June 2025) -**

'Biotech for Sustainable Growth: Rendezvous with Leaders from the Industry'

| | | | | |
|---|--|---|--|---|
|  <p>joined industry?</p> |  <p>गांधी विज्ञान केन्द्र, पुणे</p> |  |  <p>in Cancer Treatment Murali Ramachandra</p> |  |
| <p>Dr. Vilas Sinkar</p> | <p>Dr. Umesh Shaligarm</p> | <p>Prof. Pramod Wangikar</p> | <p>Dr. Murali Ramachandra</p> | <p>Dr. Amulya Panda</p> |

- **'UK Catapult Model for Deep Tech Commercialisation – A CPI Perspective'**

Hosted by BRIC-NCCS in association with DBT and the British High Commission in India (06 June 2025)

| | | |
|---|---|---|
| | | |
| Dr. Arun Harish Chief Strategy Officer Centre for Process Innovation (CPI), UK | Mr. Kris Wadrop Managing Director – Materials | Meeting with leaders from academia, industries & startups |

- **'World Bioproduct Day - The BioE3 Way 2025' - 'Urban Biomanufacturing & Industrial Waste Utilization'** (07 July 2025)

| | | | |
|--|--|---|--|
| | | | |
| Director's Introductory Address: Dr. Sharmila Bapat | Panel discussion: 'From Policy to Bioproducts: BioE3 Driving High-Performance Urban Biomanufacturing' | Local success story: Dr. Ashish Polkade, Director, BESTECO Solutions and Technologies Pvt. Ltd | Student's pitch: 'Green Buildings' Ms. Sneha Verma, PhD student, BRIC-NCCS |

- **Prof. John Barnabas Memorial Lecture: 'Advances in Molecular Diagnostics, Therapeutics and Clinical Trial Strategies'** - Inaugural lecture by Dr Manohar Furtado (President and Founder, Biology for Global Good, California, USA); co-organized by BRIC-NCCS with the Dept. of Health Sciences, Savitribai Phule Pune University, and CSIR-National Chemical Laboratory, Pune. 11 July 2025.
- **National Technology Day - 'Charkha to Chemistry: Transforming Plastic Waste into Opportunities'**
Seminar by Dr. M. Dhanalakshmi (founder of 'Plasticyle Green Foundation') and Ms. Amita Deshpande (founder of 'reCharkha'). May 2025.

- **One Year of the BioE3 Policy** (25 August 2025) – Rangoli, poster and short video contests held on the theme, ‘BioE3 at One: Green Growth, Good Jobs, Cleaner Future’, for all NCCS members.
- **Seminars** showcasing contemporary research in-house, national and international PhD students and scientists: 11 guest seminars and 17 seminars in the ‘Speak Your Science’ seminar series, and 12 talks by invited speakers were organized.
- **International Women’s Day** (March 2025) - Included:

| | |
|--|--|
|  |  |
| <p>Conversational Narrative in Hindi: * By Vandana Atre (author, journalist and 3-time cancer survivor) & Shobhana Bhide (educator, Anand Niketan). * Based on their book in Marathi on HeLa cells: “हेला पेशी - कहाणी अमर्त्य पेशींची”</p> | <p>Panel Discussion (& rangoli display) on the theme: ‘Diversity, Equity & Inclusion (DEI) in Science and Policy’</p> |

OUTREACH

More than 4000 people benefitted overall from the outreach and training initiatives of BRIC-NCCS, which include the events listed below, open days, workshops, academic initiatives and engagement in extramurally funded projects.

374 students, educators and members of the general public visited NCCS on open days. About 140 external researchers at various levels received training via training workshops conducted by BRIC-NCCS in diverse areas, including cell culture technology, bioinformatics, proteomics, bioimaging (under the PuneBiocluster, microbiology and animal experimentation). 286 students and researchers received training via participation in the academic programmes (PhD coursework, Science Academies’ Summer Training, MUHS Summer Internship Program for medical students, plus other interns from the Karya Program, the Gujarat State Biotechnology

Mission, IIT-Bombay and S. P. Pune University), and extramurally-funded projects at BRIC-NCCS. We have contributed to national capacity building by also providing quality research training to PhD students: 20 students received a PhD during this year and 132 students are currently pursuing a PhD at BRIC-NCCS.

Outreach Activities

➤ Public Talk by Nobel laureate, Aaron Ciechanover (07 February 2025)

| | | | |
|---|---|--|---|
|  |  |  |  |
| Public Talk: 'The Discovery of the Ubiquitin System: How embarrassingly simple it was' | Interactions with students | | Tree plantation on the BRIC- NCCS campus |

➤ National Science Day - Open Day (28 Feb. 2025)

| | | |
|---|---|---|
|  |  |  |
|  |  |  |

➤ International Science Festival 2024 Curtain Raiser - Open Day (08 Nov. 2024)

➤ International Science Festival (IISF 2024) (30 Nov–03 Dec 2024, IIT-Guwahati)



➤ **Education Day: 'Current Trends in Proteomics and Metabolomics'**

Organized as part of the 16th Annual Meeting of the Proteomics Society, India.
(19 Nov. 2024)

➤ **Other Extramural Outreach**

| | |
|---|--|
| <ul style="list-style-type: none"> Stem cells and biotechnological applications of animal cells Talk delivered by Dr. G. C. Mishra and Dr. S.T. Pote at Shri Shivaji Vidyalaya and Junior College, Indapur, Pune. Audience: 1500 students. 18 Dec. 2024. |  |
| <ul style="list-style-type: none"> Cervical cancer and vaccination as a preventive measure Talk delivered by Dr. Sharmila Bapat as Chief Guest at the Science Exhibition at Sant Jijabai Kanya Vidyalaya, Dehu. Audience: >1000 girl students. 15 Dec. 2024. |  |
| <ul style="list-style-type: none"> Cell culture technology and its applications Talk and demonstration of cancer cells under a microscope by Dr. Bhimashankar Utage at Yashwant Vidyalaya, Khadakwasla, Pune. Audience: ~ 200 students. 27 Nov. 2024. |  |

- Other talks delivered by Dr. Sharmila Bapat:
 - ‘कर्करोग- मूळ पेशी, रूप वैविध्य आणि वैयक्तिक उपचार’: Talk on cancer in Marathi, at the 59th All India Marathi Science Congress organized at Nanded by the Marathi Vidnyan Parishad. 11 Jan. 2025.
 - ‘**Women in Biotechnology**’: At the award function of the 5th Annual Women in Biotech Conclave & Awards, organized at Ehiraj College for Women, Chennai. 30 July 2025.
 - **Motivational Talk for School Students**: At the Annual Day Celebration at St. Joseph High School, Pune. 13 Sep. 2025.
 - **Motivational Talk for Students**: At the students’ felicitation event at Malhotra Weikfield Foundation, Pune. 14 Sep. 2025.
- ‘**Spiderman, unmasking its science**’ - Podcast presented by Dr. Deepa Subramanyam in the of ‘Sci-Fi or Sci-Fact?’ series of IndiaBioscience. 18 Feb. 2025.
- **Facilitating the creation of a ciliate model research ecosystem in India**
Dr. Santosh Kumar is helping the Dept. of Biotechnology, S. P. Pune University, Pune, and Dr. Sapan Borah from the Department of Biotechnology, NIPER, Ahmedabad, to establish *C. elegans* facilities in their respective departments.

12. Research Infrastructure

The research at BRIC-NCCS is supported by the state-of-the-art central facilities listed below, which are led by faculty members. The services offered by these facilities are also available to external researchers.

| | |
|---|---|
| <ul style="list-style-type: none"> • Bio-Imaging Facility • Proteomics Facility • Flow Cytometry Facility • Bioinformatics Facility • X ray Diffraction Facility • Surface Plasmon Resonance Facility | <ul style="list-style-type: none"> • Scanning Electron Microscope • DNA Sequencing • In vivo imaging • Experimental Animal Facility • National Cell Repository |
|---|---|

New Initiatives

- **Bioengineering Research Centre (BRC):**

The BRC, which will house microbial and mammalian cell repositories and biofoundries, is being set up at BRIC-NCCS, as an interdisciplinary Biofoundry Hub for development of precision probiotics, functional foods, and biotherapeutics, aligned with the BioE3 national policy.

- **Three new microscopes procured under the Pune Biocluster project.**

These new microscopes (listed below), were installed in the BRIC-NCCS Bioimaging Facility:

- i Multiphoton Fluorescence Microscope from Evident (Olympus)
- ii Structured Illumination microscope and localization based superresolution platform from Nikon
- iii PSF engineering based super-resolution microscope from Leica.

- **cGMP-compliant National Mammalian Cell Line Repository & Characterization Facility**

Under the aegis of the National Biopharma Mission of the Biotechnology Industry Research Assistance Council (BIRAC), a state-of-the-art cGMP-compliant national repository for mammalian cells is being set up by NCCS. This is the first of its kind in India, and is designed to meet national and global regulatory requirements. This facility will cater to the needs of the Indian biopharma and biomanufacturing industries, start-ups, bio-incubators, and researchers from academia by providing services at affordable costs, including:

- i. Cell line characterization,
- ii. Safe-deposit cell line storage, and
- iii. Cell bank preparation and characterization as per international standards (ICHQ5D).

- **BSL-3 Facility:**

A BSL-3 facility is being developed at BRIC-NCCS, which will empower advanced research on high-risk bacterial pathogens, like *Mycobacterium tuberculosis*, and viral pathogens like HIV-1 and SARS-CoV-2. These efforts are aimed at deepening

our understanding of pathogen interactions with stem cells, immune responses, and cellular pathways, ultimately guiding the development of novel therapeutics. The facility will also enable critical work on antimicrobial resistant (AMR) strains and clinical isolates, and could serve future needs in clinical diagnostics and testing of antimicrobial agents against BSL-3 pathogens. Establishing this in-house capability will significantly expand NCCS's role in national biomedical innovation.

13. Services offered

A] National Cell Repository

NCCS facilitated cell biology research across India by providing 3,688 cell cultures to 2,226 users from 550 organizations nationwide, in addition to 155 cell cultures provided to scientists at NCCS. 335 samples were tested for *Mycoplasma*, and cell line authentication of 50 cell lines was done. One cell line received from the National Brain Research Centre (NBRC), Manesar, was accepted for deposition in the repository. 44 participants (PhD scholars, postdoctoral scientists, faculty and technical staff) from 42 institutions across India benefited from two hands-on training workshops on 'Basic Cell Culture Technology' organized during this year.

B] Other Central Facilities

The central facilities are used extensively by researchers within and outside BRIC-NCCS. Over 10000 internal and external users benefited from the services provided by these central facilities through the year. The experimental animal facility supplied 3626 laboratory animals, and provided veterinary support for surgical procedures and animal experiments under approved IAEC institutional projects.

14. Number of RTIs & Grievances

| | | |
|---------------------|-------------|------------------|
| RTIs – | Received:12 | Disposed-off: 12 |
| Grievances – | Received: 8 | Disposed-off: 8 |

ANNEXURE

(Annual Report, 2024-25)

BRIC-NCCS Publications (Nov. 2024 – Oct. 2025)

Research Articles

- Avchar R, Pontes A, Lachance MA, Sharma A, Sampaio JP. *Metschnikowia ratanii* f. a. sp. nov., an ascomycetous yeast species isolated from flowers of *Lantana camara* in India. International Journal of Systematic and Evolutionary Microbiology. 2025; 75(7). <https://doi.org/10.1099/ijsem.0.006851>. PMID: 40663379
- Avchar R, Shinde S, Kashid Y, Gangani P, Sharma A. *Exophiala zingiberis* sp. nov., a novel cellulase-producing black yeast-like fungi isolated from ginger in India. International Journal of Systematic and Evolutionary Microbiology. 2024; 74(12). 1-14. <https://doi.org/10.1099/ijsem.0.006614>. PMID: 39699938
- Bagal R, Bahir M, Lenka N, Patro TU. Graphene oxide facilitates osteo-differentiation of mesenchymal stem cells in 3-dimensional porous vitreous carbon foam scaffolds. ACS Applied Bio Materials. 2025; 8(9):8010-8021. <https://doi.org/10.1021/acsabm.5c00996>. PMID: 40851302
- Bertagna MA, Bright LJ, Fei Ye, Jiang YY, Sarkar D, Pradhan A, Kumar S, Gao S, Turkewitz AP, Tsypin LMZ. Inferring gene-pathway associations from consolidated transcriptome datasets: An interactive gene network explorer for *Tetrahymena thermophila*. NAR Genomics and Bioinformatics. 2025; 7(2)lqaf067. <https://doi.org/10.1093/nargab/lqaf067>. PMID: 40432793
- Bharti P, Assaiya A, Dawath BK, Kumar J. Cornichons: Evolution, AMPA receptor modulation, and emerging roles beyond the nervous system. Brain Disorders. 2025; 19:100245. <https://doi.org/10.1016/j.dscb.2025.100245>
- Bhattacharya D, Jiya N, Mondal S, Acharya A, Chatterjee A, Bakshi U, Sharma A. Bacterial diversity in the freshwater sponges of Sundarban and their potential role in biomonitoring toxic element pollution. Microbiology Spectrum. 2025; 13(10): e02149-25. <https://doi.org/10.1128/spectrum.02149-25>. PMID: 40862605
- Chatterjee B, Mande SC. Demography, sanitation and previous disease prevalence associate with COVID-19 deaths across Indian states. Scientific Reports. 2025; 15: 10270. <https://doi.org/10.1038/s4543420/v1>. PMID: 40133381

- Chaturvedi S, Karandikar M, Mundada P, Tripathy S, Kolhe R, Yadav B, Rana R, Gautam PC, Satoor S, Phalke T, Suryawanshi P, Khanduri S, Rao B, Srikanth N, Patwardhan B. Daily intranasal sesame oil instillation to improve nasal barrier function and mucosal immunity for respiratory health: A pilot randomized trial in healthy adults. *Complementary Therapies in Medicine*. 2025; (93):103210. <https://doi.org/10.1016/j.ctim.2025.103210>. PMID: 40716461
- Crous PW, Sharma A, JZ Groenewald. Fungal planet description sheets: 1697–1780. *Fungal Systematic Evolution*. 2024; 6:14:325–577. <https://doi.org/10.3114/fuse.2024.14.19>. PMID: 39830292
- Dasgupta A, Tripathi A, Mitra A, Ghosh P, Santra MK, Mitra D. Human microRNA miR-197-3p positively regulates HIV-1 virion infectivity through its target DDX52 by stabilizing Vif protein expression. *Journal of Biological Chemistry*. 2025; 301(2): 108198. <https://doi.org/10.1016/j.jbc.2025.108198>. PMID: 39826696
- Deo PN, Deshmukh RS, Gaike AK, Christopher A, Gujare M, Inamdar M. Oral microbiome profiles in oral potentially malignant disorders and oral cancer - A diagnostic perspective. *Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology*. 2025;29(1):87-97. https://doi.org/10.4103/jomfp.jomfp_140_24. PMID: 40248614
- Dixit A, Ahmed A, Singh A, Inamdar M, Chavan S, Bodkhe R, Mehtab W, Chauhan A, Saroj SD, Ahuja V, Shouche Y, Dhotre D, Makharia G. Site-specific gut microbial signatures in non-celiac gluten sensitivity. *Gut Microbes Reports*. 2024; 1(1): 1-11. <https://doi.org/10.1080/29933935.2024.2438621>
- Dubey S, Bhattacharjee A, Oza Y, Saxena SS, Pradhan S, Sharma A, Sharma S. Harnessing SynComs for rhizosphere engineering to alleviate salt stress in *Vigna radiata*: From lab experiments to the field. *Plant Physiology and Biochemistry*. 2025; 229(PtA):110304. <https://doi.org/10.1016/j.plaphy.2025.110304>. PMID: 40780107
- Fernandes SO, Paul D, Lankalapalli SP, Rao AS; Vidya PJ, Kurian J. Upper circumpolar deep water influences microbial functional gene composition and diversity along the southern Central Indian Ridge and eastern Southwest Indian Ridge. *Microbiology Spectrum*. 2024; 13 (2): 1-18. <https://doi.org/10.1128/spectrum.03306-23>. PMID: 39727810

- Gaikwad N, Sarwade R, Halder S, Agarwal G, Seshadri V. HuD regulates apoptosis in N2a cells by regulating Msi2 expression. *PLoS One.* 2024; 9(12):e0315535. <https://doi.org/10.1371/journal.pone.0315535>. PMID: 39680531
- Guha A, Prasad A, Ashokkumar K, Pal P, Sahu P, Wani MR, Lal G. Complement C3 deficiency inhibits osteoclast differentiation and prevents ovariectomy-induced osteoporosis. *Journal of Immunolgy.* 2025; *vkaf180.* <https://doi.org/10.1093/jimmun/vkaf180>. PMID: 40847478
- Guhe V, Singh S. Uncovering the significance of JNK/AKT axis in the autophagic regulation of *Leishmania major* Infection. *Molecular Microbiology.* 2024; 123 (1): 1-15. <https://doi.org/10.1111/mmi.15333>. PMID: 39626091
- Gupta R, Shravan S, Agwane SB, Bankar RM, Bapat SA. ID8 cells manifest phenotypic plasticity and molecular heterogeneity of high-grade serous ovarian cancer in response to the local tissue niche. *Scientific Reports.* 2025; 15(1):34626. <https://doi.org/10.1038/s41598-025-18264-8>. PMID: 41044210
- Jadab M, Pradhan KC, Behera S, Agrawalla SK, Barik S, Purohit CS, Samanta S, Santra MK, Kumar J, Pal S. Luminescent platinum(II) complexes featuring innocent pyridine-2-aldoxime ligand: Synthesis, characterization, and exploration of their in vitro cytotoxicity properties. *ChemistrySelect.* 2025; 10(17): e202500328. <https://doi.org/10.1002/slct.202500328>
- Jamdhade MD, Shivalingappa PKM, Atre AN, Mahale KN, Patole MS, Pawar H. Characterization of NUDIX hydrolase from *Leishmania major*. *Acta Parasitologica.* 2025; 70(3):124. <https://doi.org/10.1007/s11686-025-01065-4>. PMID: 40459658
- Jiya N, Sanap A, Srivastava S, Kheur S, Sharma A. Microbial signatures in oral submucous fibrosis and oral squamous cell carcinoma: Implications of tobacco and betel quid consumption. *Journal of Oral Biosciences.* 2025; 67(2):100656. <https://doi.org/10.1016/j.job.2025.100656>. PMID: 40127779
- Joshi A, Thite S, Godbole D, Boruah D, Sindhu DK, Prabhu A, Joseph N, Yadav A, Sharma A, Lodha T. Genomic insights into *Marinospirillum alkalitolerans* sp. nov., a novel PHB producing bacterium from an Indian impact crater, and an emended description of family Oceanospirillaceae. *Antonie van Leeuwenhoek.* 2025; 118(3):53. <https://doi.org/10.1007/s10482-024-02059-4>. PMID: 39928221
- Kavungal D, Morro E, Senthil TK, Dagli B, Lashuel HA, Altug H. Nanoplasmonic infrared microarray sensor enabling structural protein biomarker-based drug

screening for neurodegenerative diseases. Advanced Science. 2025; e00320. <https://doi.org/10.1002/advs.202500320>. PMID: 40719288

- Keer A, Oza Y, Mongad D, Ramakrishnan D, Dhotre D, Ahmed A, Zumla A, Shouche Y, Sharma A. Assessment of seasonal variations in antibiotic resistance genes and microbial communities in sewage treatment plants for public health monitoring. Environmental Pollution. 2025; 375:126367. <https://doi.org/10.1016/j.envpol.2025.126367>. PMID: 40320120
- Khandibharad S, Gulhane P, Singh S. Computational cellular mathematical model aids understanding the cGAS-STING in NSCLC pathogenicity. Bio-protocol. 2025;15 (5): e5223. <https://doi.10.21769/BioProtoc.5223>. PMID: 40084069
- Kirdat K, Patwekar U, Jain K, Mubarak M, Choudhary P, Thakkar L, Thorat V, Madamwar D, Lodha T, Yadav A. Genomic insights into *Neopusillimonas aestuarii* sp. nov., a novel estuarine bacterium with adaptations for ectoine biosynthesis and stress tolerance. Antonie van Leeuwenhoek. 2025; 118(6):82. <https://doi.org/10.1007/s10482-025-02093-w>. PMID: 40418388
- Kumar CM, Mai AM, Mande SC, Lund PA. Genetic and structural insights into the functional importance of the conserved gly-met-rich C-terminal tails in bacterial chaperonins. Communications Biology. 2025; 8(1):555. <https://doi.org/10.1038/s42003-025-07927-x>. PMID: 40200084
- Kumar G, Khandibharad S, Singh S. Targeting IL-6/STAT3 signaling to mitigate sarcopenia: Insights from immuno-metabolic crosstalk in NSCLC. Biochemical and Biophysical Research Communications. 2025; 786:152727. <https://doi.org/10.1016/j.bbrc.2025.152727>. PMID: 41038071
- Kumar P, Kinger S, Dubey AR, Jagtap YA, Choudhary A, Karmakar S, Lal G, Kumar G, Bhattacharyya A, Poluri S, Krishna Mohan, Mishra A. Ketonolac disturbs proteasome functions and induces mitochondrial abnormality-associated apoptosis. IUBMB Life. 2025; 77(1): e2937. <https://doi.org/10.1002/iub.2937>. PMID: 39723629
- Kumar S, Agrawal P, Mendhey P, Dhatwalia SK, Sitasawad SL. Antioxidants ameliorates glucose/glucose oxidase-induced myocardial damage through mitochondrial and MAPK pathway. 3Biotech. 2025; 15(9):323. <https://doi.org/10.1007/s13205-025-04441-z>. PMID: 40900813

- Kumar S, Das S, Jiya N, Sharma A, Saha C, Sharma P, Tamang S, Thakur N. Bacterial diversity along the geothermal gradients: Insights from the high-altitude Himalayan hot spring habitats of Sikkim. *Current Research in Microbial Sciences*. 2024; 7:100310. <https://doi.org/10.1016/j.crmicr.2024.100310>. PMID: 39629478
- Maity S, Dubey DK, Upreti A, Chowdhury S, Chandpa HH, Meena J, Kumar A, Sahu RC, Agrawal AK, Santra MK, Maiti P. Mechanically responsive organic-inorganic hybrid as advanced delivery vehicle for targeted cancer treatment. *Advanced Healthcare Materials*. 2025; 14(19):e2500738. <https://doi.org/10.1002/adhm.202500738>. PMID: 40474441
- Marathe S, Chougule H, Nikam V, Majumdar A, Bose T. Functional activities of cohesin proteins can be altered by chemical chaperone. *The Protein Journal*. 2025; 44(5):550-569. <https://doi.org/10.1007/s10930-025-10276-7>. PMID: 40668332
- Mondal A, Barik GK, Sarkar S, Shivpuje U, Mondal J, Santra MK, Talukdar P. Apoptosis-Inducing Activity of a 2-hydroxyphenyl benzamide-based self-assembled anion channel. *Chemistry: A European Journal*. 2025; 31 (3): e202403252. <https://doi.org/10.1002/chem.202403252>. PMID: 39614826
- Mondal S, Karande M, Srivastava S, Sharma A, Sharma S, Ghosh A. Unravelling the microbiome perspective to variations in tea metabolome. *Industrial Crops and Products*. 2025; 223: 120129. <https://doi.org/10.1016/j.indcrop.2024;120129>
- More N, Joseph J. Disruption of ER–mitochondria contact sites induces autophagy-dependent loss of P-bodies through the Ca²⁺-CaMKK2-AMPK pathway. *Journal of Cell Science*. 2025; 138(5): JCS263652. <https://doi.org/10.1242/jcs.263652>. PMID: 40071500
- Mujawar SS, Arbade GK, Neema B, Mane M, Tripathi V, Sharma RK, Kashte SB. 3D printed *Aloe barbadensis* loaded alginate-gelatin hydrogel for wound healing and scar reduction: In vitro and in vivo study. *International Journal of Biological Macromolecules*. 2025; 296:139745. <https://doi.org/10.1016/j.ijbiomac.2025.139745>. PMID: 39800028
- Mujawar SS, Arbade GK, Rukwal S, Tripathi V, Mane M, Sharma RK, Kashte SB, 3D printed sodium alginate-gelatin hydrogel loaded with *Santalum album* oil as an antibacterial full-thickness wound healing and scar reduction scaffold: In vitro and in vivo study. *International Journal of Pharmaceutics*. 2025; 10:670:125164. <https://doi.org/10.1016/j.ijpharm.2024.125164>. PMID: 39756601

- Munavar KF, Lenka N. Deubiquitinating enzymes at the crossroads of blood–brain barrier integrity and neurodegeneration: mechanistic insights, therapeutic targeting and future directions. *Tissue Barriers*. 2025; 2504738. <https://doi.org/10.1080/21688370.2025.2504738>. PMID: 40358463
- Murugesan S, Patil HG, Deshmukh BK, Sreejisha N, Asokan A, Mohapatra A, Lenka N, Anandhan S. Development of electrospun scaffolds for bone regeneration from strontium-doped hydroxyapatite nanorods and thermoplastic polyurethane elastomer. *Polymer*. 2025, 334:128703. <https://doi.org/10.1016/j.polymer.2025.128703>
- Nadodkar SD, Karande M, Pawar MG, Dhume AV, Sharma A, Salgaonkar BB. Deciphering the salt induced morphogenesis and functional potentials of *Hortaea werneckii*, a black pigmented halotolerant yeast isolated from solar saltern. *Fungal Biology*. 2024; 128 (7): 2113-2126. <https://doi.org/10.1016/j.funbio.2024.08.010>. PMID: 39384281
- Narayanan A, Guha S, Mali A, Bapat SA. Targeting mitochondrial translation and OXPHOS in high-grade serous ovarian carcinoma eliminates stem-like cells. *Cell Death & Disease*. 2025; 16 (676). <https://doi.org/10.1038/s41419-025-07987-1>. PMID: 41053051
- Narayanan A, More AS, Talreja M, Mali AM, Boya Vinay S, Bapat SA. A novel ITGB8 transcript variant sustains ovarian cancer cell survival through genomic instability and altered ploidy on a mutant p53 background. *Journal of Ovarian Research*. 2024; 17(1):218. <https://doi.org/10.1186/s13048-024-01538-6>. PMID: 39506768
- Nazirahmed S, Rahi P, Saxena H, Singh A, Panchal RK. High prokaryotic diversity in the oxygen minimum zone of the Bay of Bengal: Implications for nutrient cycling. *Aquatic Microbial Ecology*. 2025; 91:31-51. <https://doi.org/10.3354/ame02016>
- Negi S, Singh P, Rawat B, Sharma A, Rawat JM, Semwal P. Unearthing the landscape: A bibliometric exploration of hairy root culture research over the past 41 years. In *In Vitro Cellular & Developmental Biology - Plant*. 2025; <https://doi.org/10.1007/s11627-024-10488-z>
- Nimal S, Kumbhar N, Pote MS, Bankar R, Shaikh M, Gacche R. Reversal of epithelial to mesenchymal transition in triple negative breast cancer through epigenetic modulations by dietary flavonoid galangin and its combination with

SAHA. Cell Communication and Signaling. 2025; 23(1):163. <https://doi:10.1186/s12964-025-02174-3>. PMID: 40176095

- Oza Y, Sharma SS, Karande M, Khanal M, Pradhan A, Rawat S. Sharma A. Symbiotic association of rhizobiome with newly discovered *Gastrodia indica*, a holomycotrophic orchid species from eastern Himalayas. Biologia. 2025; 80: 2859 – 2869. <https://doi.org/10.1007/s11756-025-02019-x>
- Pampana SVL, Biswas B, Jajula S, Rapole S, Ummanni R. Proteomic analysis of microsomal proteins reveals that MVP is crucial for the secretion of GDF-15, which in turn promotes the neuroendocrine differentiation of PCa cells. Journal of Proteome Research. 2024; 23 (12): 5540–555. <https://doi.org/10.1021/acs.jproteome.4c00694>. PMID: 39472282
- Pawar GM, Naik SV, Naik TJ, Karande M, Sharma A, Salgaonkar BB. Biodegradation of crustacean shell waste by *Halococcus salsus* GUAg20; a chitinolytic and proteolytic halophilic archaeon. International Biodeterioration & Biodegradation. 2025; 202: 106102. <https://doi.org/10.1016/j.ibiod.2025.106102>
- Piprde V, Behera S, Karhade J, Mhaske ST, Wani MR. Priming of mouse pre-osteoblasts with Interleukin-3 attenuates TNF- α -induced-inhibition of osteoblast differentiation. BMC Musculoskeletal Disorders. 2025; 26(1):663 <https://doi:10.1186/s12891-025-08610-2>. PMID: 40624526
- Prasad R, Preerna K, Temgire M, Banerjee P, Kumari R, Kundu GC, Hattila D, Mangannavar CV, Singh AM, Gorain M, Bellare J, Chandra P, Dubey VK, Molecular engineering of ultrabright biomimetic nanoghost for site-selective tumor imaging and biodistribution. Advanced Healthcare Materials. 2025; 14(3):e2401233. <https://doi:10.1002/adhm.202401233>. PMID: 39629548
- Rahman M, Uddin M, Ashrafi SAA, Rahman KM, Paul KK, Ferdous M, Sarker R, Haque F, Sharma A*, Papakonstantinou D. The 2023 fatal dengue outbreak in Bangladesh highlights a paradigm shift of geographical distribution of cases. Epidemiology & Infection. 2025; 153:e3. <https://doi.org/10.1017/S0950268824001791>. PMID: 39763239
- Rekadwad BN, Shouche YS, Jangid K. Oil spill pollution and diversity analyses of resistant bacteria isolated from soil across the Arabian Sea and Bay of Bengal coastlines. Environmental Monitoring and Assessment. 2024;196(12):1265. <https://doi.org/10.1007/s10661-024-13428-x>. PMID: 39601988

- Sayantan P, Mandal K, Santra MK, Bhattacharya AK, Cyclopropane containing triterpenoids, cycloartenone, and cycloartenol: Isolation, chemical transformations, and anticancer studies. *ChemistrySelect.* 2025; 10:9: e202403698. <https://doi.org/10.1002/slct.202403698>
- Sharan K, Brandt C, Yusuf MA, Singh P, Halder N, Edwards ME, Mangu S. V. V. S, Das R, Mishra A, Kumar A, Shashi S.S, Gupta A, A, Liu XS, Guo EX, Monani UR, Ponnalagu D, Ivanov II, Lal G, Clare S, Dougan G, Yadav VK, Rapid and relaying deleterious effects of a gastrointestinal pathogen, *Citrobacter rodentium*, on bone, an extra-intestinal organ. *iScience.* 2025; 16:28(2):111802. <https://doi.org/10.1016/j.isci.2025.111802>. PMID: 39967874
- Sharma H, Yadav R, Singh D, Goel B, Seshadri V, Kapoor S, Kapoor M. Transfer RNA aspartic acid methyltransferase 1 (TRDMT1/DNMT2) regulates plant development and gene expression in the moss *Physcomitrium patens*. *Molecular Genetics and Genomics.* 2025; 300(1):88. <https://doi.org/10.1007/s00438-025-02285-z>. PMID: 40905999
- Sharma V, Chhawari H, Joshi1 P, Nehra S, Singhal N, In vitro modeling of Down syndrome neurogenesis using human-induced pluripotent stem cells. *JOVE: Journal of Visual Experiments.* 2025; (217): 67382. <https://doi.org/10.3791/67382>. PMID: 40127053
- Singh S, Srivastava SK, Gahtori P, Anand AA, Kumar SS, Kumawat MK, Bhat HR, Corona A, Tramontano E, Mitra D, Singh UP. Design and synthesis of 2,4-thiazolidinedione substituted 1,3,5-triazine derivatives as anti-HIV agent via inhibition of reverse transcriptase along with anti-SARS CoV-2, antibacterial and antibiofilm activity. *Bioorganic Chemistry.* 2025; 160:108427. <https://doi.org/10.1016/j.bioorg.2025.108427>. PMID: 40187029
- Sinha S, Khonde V, Mirza Y, Nandi S, Dhotre D, Ghosalkar A. Isolation and characterization of a bacteria of *Cupriavidus* genus from Indian Himalayan region and its evaluation for production of poly-3-hydroxybutyrate. *Archives of Microbiology.* 2025; 207(231). <https://doi.org/10.1007/s00203-025-04425-w>. PMID: 40833483
- Susmitha A, Reddy GJ. 3D-hNCAnH for simultaneous backbone resonance assignment and one and two bond N–Ca coupling constants for secondary

structural prediction of proteins. *Magnetic Resonance in Chemistry*. 2025; 0:1-11. <https://doi.org/10.1002/mrc.70040>. PMID: 40944571

- Tambekar A, Guhe V, Singh S. The cGAS-STING mediated crosstalk between innate immunity and autophagy in leishmaniasis using mathematical modeling: Uncovering new therapeutic avenues. *Archives of Biochemistry and Biophysics*. 2024; 762: 110201. <https://doi.org/10.1016/j.abb.2024.110201>. PMID: 39486567
- Tiwari M, Dingankar M, Das J, Sreelekshmi S R, Solanki A, Subramanyam D. CLCa mediates a novel cross-talk between Wnt secretion and actin organization. *Life Science Alliance*. 2025; 8(7):e202402962. <https://doi:10.26508/lsa.202402962>. PMID: 40316417
- Tyagi R, Oza Y, Sarkar A, Shivay YS, Sharma A, Sharma S. Mapping the pathobiome and rhizosphere microbiome in *Cajanus cajan*-*Fusarium* interaction across agroclimatic zones and crop varieties. *Plant and Soil*. 2025; 513: 737-757. <https://doi.org/10.1007/s11104-025-07208-w>
- Vadankula GR, Rizvi A, Ali H, Khunjamayum R, V. V. Eedara V V R, Nema V, Singh DN, Babu KS, Shetty PR, Mande SC, Banerjee S. Secondary Metabolites from a new antibiotic-producing endophytic *Streptomyces* isolate inhibited pathogenic and multidrug-resistant *Mycobacterium tuberculosis* strains. *Tropical Medicine and Infectious Disease*. 2025; 10(5): 117. <https://doi.org/10.3390/tropicalmed10050117>. PMID: 40423347
- Verma N, Chavan N, Aulakh KS, Sharma A, Shouche Y, Venkata Ramana VV. Temporal dynamics of microbial community composition and antimicrobial resistance in a mass gathering setting using culturomics and metagenomic approaches. *Journal of Epidemiology and Global Health*. 2025; 15(1):41. <https://doi.10.1007/s44197-025-00382-1>. PMID: 40072675
- Verma S, Kirdat K, Rao GP, Yadav A. Genome-informed perspectives on '*Candidatus Phytoplasma sacchari*' and sugarcane grassy shoot disease. *Sugar Tech*. 2025; 1-6. <https://doi.org/10.1007/s12355-025-01670-7>
- Yadav A, Kirdat K, Thorat V, Tuikhar N, Chundawat K, Lodha T, Tiwarekar B, Patwekar U, Mubarak M, Shastri S, Kumar S. Description of high-altitude, cold-adaptive, metabolically versatile *Dyadobacter aurulentus* sp. nov. isolated from Western Himalayan farmland soils. *Microbiology Spectrum*. 2025; e01145-25. <https://doi.org/10.1128/spectrum.01145-25>. PMID: 41065371

- Yu-Yang J, Kumar S, Turkewitz AP. The secretory pathway in *Tetrahymena* is organized for efficient constitutive secretion at ciliary pockets. *iScience*. 2024; 27(11): 1111123. <https://doi.org/10.1016/j.isci.2024.111123>. PMID: 39498308

Reviews

- Bammigatti A, Ghosh SK, Bandyopadhyay S, Saha B. Messages in CD40L are encrypted for residue-specific functions. *Cytokine*. 2025; 185:156824. <https://doi.org/10.1016/j.cyto.2024.156824>. PMID: 39615244
- Bhanuse SG, Kalita B, Taunk K, Rapole S. Unveiling the multifaceted role of MZB1 in health and disease toward potential therapeutics. A comprehensive review. *International Journal of Biological Macromolecules*. 2025; 321(4): 146399. <https://doi.org/10.1016/j.ijbiomac.2025.146399>. PMID: 40738426
- Bhati FK, Bhat MK. An anti-neoplastic tale of metformin through its transport. *Life Science*. 2024; 357(15):123060. <https://doi.org/10.1016/j.lfs.2024.123060>. PMID: 39278619
- Bhavsar PP, Kalita B, Taunk K, Rapole S. Decoding the key hallmarks of chemoresistance: A proteomic tale from breast cancer research. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*. 2025; 1880(5):189404. <https://doi.org/10.1016/j.bbcan.2025.189404>. PMID: 40750088
- Chitale GG, Kulkarni SR, Bapat SA. Chimerism: A whole new perspective in gene regulation. *Biochimica et Biophysica Acta (BBA) - General Subjects*. 2025; 1869(3):130767. <https://doi.org/10.1016/j.bbagen.2025.130767>. PMID: 39855315
- Dash UC, Nayak V, Navani HS, Samal RR, Agrawal P, Singh AK, Majhi S, Mogare DG, Duttaroy AK, Jena AB. Understanding the molecular bridges between the drugs and immune cell. *Pharmacology & Therapeutics*. 2025; 267:108805. <https://doi.org/10.1016/j.pharmthera.2025.108805>. PMID: 39908660
- Halder N, Yadav S, Lal G. Neuroimmune communication of the cholinergic system in gut inflammation and autoimmunity. *Autoimmunity Reviews*. 2024; 23(12):103678. <https://doi.org/10.1016/j.autrev.2024.103678>. PMID: 39500481
- Khandibharad S, Singh S. Epigenetic landscape of *Leishmania*-host interactions. *Epigenomics*. 2025; <https://doi.org/10.1080/17501911.2025.2574836>. PMID: 41099169

- Khilwani R, Singh S. Leveraging evolutionary immunology in interleukin-6 and interleukin-17 signaling for lung cancer therapeutics. *ACS Pharmacology & Translational Science*. 2024; 7(12):3658-3670. <https://doi.org/10.1021/acsptsci.4c00412>. PMID: 39698267
- Mandal K, Barik GK, Santra MK. Overcoming resistance to anti-PD-L1 immunotherapy: Mechanisms, combination strategies, and future directions. *Molecular Cancer*. 2025; 24(1):246. <https://doi.org/10.1186/s12943-025-02400-z>. PMID: 41057853
- Pal P, Wahi P, Sahu A, Lal G. Pro- and anti-inflammatory role of complement in cancer. *European Journal of Immunology*. 2026; 55(6).E51767. <https://doi.org/10.1002/eji.202451767>. PMID: 40498246
- Parker S, Steffen R, Rashid H, Cabada MM, Memish ZA, Gautret P, Sokhna C, Sharma A, Shlim DR, Leshem E, Dwyer DE, Lami F, Chatterjee S, Shafi S, Zumla A, Mahomed O. Sacred journeys and pilgrimages: health risks associated with travels for religious purposes. *Journal of Travel Medicine*. 2024; 31(8) taae122. <https://doi.org/10.1093/jtm/taae122>. PMID: 39216102
- Ranjan S, Choudhary P, Shivalkar S, Dwivedi S, Singh S. Potential of hyaluronic acid and collagen-based scaffolds in promoting stem cell neuronal differentiation for neuroregenerative therapies: A review. *International Journal of Biological Macromolecules*. 2025; 309(3):142981. <https://doi.org/10.1016/j.ijbiomac.2025.142981>. PMID: 40216130
- Sharma S, Das J, Subramanyam D. Traffic flow and signals: Regulating the movement within cells. *Current Opinion in Cell Biology*. 2025; 94:102518. <https://doi.org/10.1016/j.ceb.2025.102518>. PMID: 40239282
- Solyga M, Majumdar A, Besse F. Regulating translation in aging: From global to gene-specific mechanisms. *EMBO Report*. 2024; 25(12):5265-5276. <https://doi.org/10.1038/s44319-024-00315-2>. PMID: 39562712
- Yadav S, Veliventi SS, Bhandari S, Gangurde S, Naik S, Bhagwat SN, Kumar S. Decoding GNAO1 mutations using *Caenorhabditis elegans* model system: Past approaches and future prospectives. *Frontiers in Cellular Neuroscience*. 2025; 19:1633744. <https://doi.org/10.3389/fncel.2025.1633744>. PMID: 40771566

Book Chapters/Edited Books/Meeting Reports/Others

- Das G, Malak OA, Sharma K, Alia AG, Gopalakrishnan S, Menon RV, Yamanouchi HM, Nose A, Kazama H, Moore AW, Suzuki T. The fly brain lands in Tokyo: A report on the 3rd Asia Pacific *Drosophila* Neurobiology Conference. *Genes to Cells*. 2024; 29:12. (Meeting Report). <https://doi.org/10.1111/gtc.13178>
- Dhotre D, Karmarkar B. 10 - Metagenomics-guided reengineering of the gut microbiome. Book - Metagenomics (Second Edition) Perspectives, Methods, and Applications. Edited by: Muniyandi Nagarajan. Published: 2024. Academic Press. ISBN: 978-0-323-91631-8. DOI: 10.1016/C2021-0-00003-1. 2024; Pages 225-264. <https://doi.org/10.1016/B978-0-323-91631-8.00011-1>
- Halder N, Wahi P, Lal G. (2024). Role of neurotransmitters in inflammation and autoimmunity. *Inflammation*. Volume 4. Published by the Society of Inflammation Research-India. ISBN:9788196913304. <https://doi.indiainflammation.org/>
- Karmakar S, Suresh R, Yadav S, Lal G. Unconventional T Cells: Biology, Functions, and Their Implications in Cancer. Chapter. *Cell-based Immunotherapies for Cancer*. Mishra AK, Malonia SK. 2025: pp 255–280. Springer Nature. https://doi.org/10.1007/978-3-031-88695-9_10
- Lal G. Editor: *Inflammation*, Volume 4. Published by Society of Inflammation Research-India. 2024; ISBN 978-81-6913304. <https://doi.indiainflammation.org/>
- Oza Y, Bagade S, Sharma A. Geomicrobiology in Hot Spring Hydrothermal Systems. Chapter, First Online: Mineral Transformation and Bioremediation by Geo-Microbes. *Interdisciplinary Biotechnological Advances (IBA)*. 13, 2025; pp 45–63 (Book Chapter). https://doi.org/10.1007/978-981-96-3033-2_3
- Sonar SS, Lal G. Chapter 1- Overview of Mechanisms Underlying Neuroimmune Diseases. *Neuroimmune Diseases*. Editors: Hiroshi Mitoma, Mario Manto. 2024; pp 3–76.https://doi.org/10.1007/978-3-031-60006-7_1
- Yadav A. A Perspective on Bridging Legacy Systems and Genomic Advances in Transiting Phytoplasma Taxonomy. *The Bulletin of BISMIS*. 2025; 18;8(1):5. <https://doi.10.5281/zenodo.17140656>

National Centre For Cell Science
An Autonomous Institute of
Department of Biotechnology, Govt of India
NCCS Complex, Savitribai Phule Pune University Campus, Ganeshkhind,
Pune 411007.

AUDITED STATEMENTS OF ACCOUNT

FOR
F.Y. 2024-2025

AUDITORS

M/S M S B S & COMPANY
CHARTERED ACCOUNTANTS

18, RAMTIRTH BUNGLOW, LAXMIPARK COLONY
NEAR BHIDE HOSPITAL, NAVI PETH
Pune - 411030.
Tel : 020-2999 5226

msbs@camsbs.com



INDEPENDENT AUDITOR'S REPORT

To
The Director,
NCCS Complex, P.B. No.40,
Ganesh Khind P.O.,
Pune-411007

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of National Centre For Cell Science ("the Institute"), which comprise the Balance Sheet as at 31st March, 2025, and the Income and Expenditure Account for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion and to the best of our information and according to the explanations given to us, the acening financial statements give a true and fair view of the financial position of the Institute as at 31st March, 2025, and of its financial performance for the year ended in accordance with the Accounting Standards issued by the Institute of Chartered Accountants of India ("the ICAI"), The Maharashtra Public Trust Act 1950, read with the common format of accounts for all Autonomous Institute as per letter No. BT/MED/NCCS/ADMN/2002 dated June 10, 2002 of Department of Biotechnology, New Delhi and Comptroller & Auditor General of India (CAG) letter No. OA-VII(MISC/CORRES/2002-03/1165) dated October 16, 2002.

Basis for Opinion

We conducted our audit in accordance with Standards on Auditing (SAs) issued by the ICAI. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Institute in accordance with the ethical requirements that are relevant to our audit of the financial statements, and we have fulfilled our other responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with The Maharashtra Public Trust Act 1950, read with the common format of accounts for all Autonomous Institute as per letter No. BT/MED/NCCS/ADMN/2002 dated June 10, 2002 of Department of Biotechnology, New Delhi and Comptroller & Auditor General of India (CAG) letter No. OA-VII (MISC/CORRES/ 2002-03/1165) dated October 16, 2002 and for design, implementation and maintenance of internal control as management determines is necessary to enable the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Institute's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Institute or to cease operations, or has no realistic alternative but to do so. Those charged with governance are responsible for overseeing the Institute's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional scepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

We report that

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of Financial Statements
- b) In our opinion, proper books of account as required by law have been kept by the Institute so far as it appears from our examination of those books
- c) The Balance Sheet, Statement of Income and Expenditure dealt with by this Report are in agreement with the books of account

**For M/s. M S B S & Company
Chartered Accountants
Firm Reg. No. 136148W**



Nitin Mulik

Partner

M. No. 165937

UDIN:25165937BMLZMF2606

Place: Pune

Date: 24th June,2025



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007

BALANCE SHEET AS AT 31.03.2025

Amount (Rs.)

| CORPORUS/CAPITAL FUND AND LIABILITIES | Schedule | 31.03.2025 | 31.03.2024 |
|---|----------|--------------------------|--------------------------|
| CORPORUS/CAPITAL FUND | 1 | 1,39,40,87,053.80 | 1,15,09,23,918.36 |
| RESERVES AND SURPLUS | 2 | - | - |
| EARMARKED/ENDOWMENT FUNDS | 3 | 15,02,87,576.64 | 18,01,89,655.96 |
| SECURED LOANS AND BORROWINGS | 4 | - | - |
| UNSECURED LOANS AND BORROWINGS | 5 | - | - |
| DEFERRED CREDIT LIABILITIES | 6 | - | - |
| CURRENT LIABILITIES AND PROVISIONS | 7 | 7,12,96,672.21 | 5,71,56,521.89 |
| Total | | 1,61,56,71,302.65 | 1,38,82,70,096.21 |
| ASSETS | | | |
| FIXED ASSETS | 8 | 1,01,00,76,916.00 | 76,34,65,541.00 |
| INVESTMENTS FROM EARMARKED / ENDOWMENT FUNDS | 9 | - | - |
| INVESTMENTS OTHERS | 10 | - | - |
| CURRENT ASSETS, LOANS, ADVANCES | 11 | 60,55,94,386.65 | 62,48,04,555.21 |
| MISCELLANEOUS EXPENDITURES (to the extent not written off or adjusted) | | - | - |
| Total | | 1,61,56,71,302.65 | 1,38,82,70,096.21 |
| SIGNIFICANT ACCOUNTING POLICIES | 24 | | |
| CONTINGENT LIABILITIES AND NOTES ON ACCOUNTS | 25 | | |

The schedules referred to above form an integral part of the Balance Sheet.

As per our report of even date.

Date: 24th June, 2025

Place: Pune

OFFICER 'C' ACCOUNTS

NCCS

वैभव आ. अरगडे

Vaibhav A. Argade

अधिकारी 'ग' (लेखा)

Officer "C" (Accounts)

रा.को.वि.के./NCCS Pune-411007



DIRECTOR (ADDL. CHARGE)

NCCS

निदेशक(अतिरिक्त प्रभार)

राष्ट्रीय कोशिका विज्ञान केन्द्र, पुणे

Director (Addl. Charge)

National Centre for Cell Science, Pune

FOR M/s. M S B S & COMPANY
CHARTERED ACCOUNTANTS
FIRM REG. NO. 136148W



NITIN MULIK
PARTNER
M.NO.165937

Date: 24th June, 2025

Place: Pune

UDIN:25165937BMLZMF2606



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007

INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31.03.2025

Amount (Rs.)

| INCOME | Schedule | 2024-25 | 2023-24 |
|---|----------|------------------------|------------------------|
| INCOME FROM SALES/SERVICE | 12 | 1,61,39,443.00 | 1,25,64,951.00 |
| GRANTS/SUBSIDIES | 13 | 52,71,05,529.00 | 49,99,85,470.00 |
| FEES/SUBSCRIPTIONS | 14 | 21,85,235.00 | 20,14,238.00 |
| INCOME FROM INVESTMENTS | 15 | - | - |
| INCOME FROM ROYALTY, PUBLICATION ETC. | 16 | 39,759.30 | - |
| INTEREST EARNED | 17 | 36,91,929.00 | 36,06,289.00 |
| OTHER INCOME | 18 | 49,31,311.00 | 30,45,622.39 |
| INCREASE/(DECREASE) IN STOCK OF FINISHED GOODS & WORK IN PROGRESS | 19 | - | - |
| TOAL (A) | | 55,40,93,206.30 | 52,12,16,570.39 |
| EXPENDITURE | | | |
| ESTABLISHMENT EXPENSES | 20 | 26,87,58,565.00 | 25,00,91,129.00 |
| OTHER ADMINISTRATIVE EXPENSES | 21 | 25,93,47,813.86 | 24,97,99,071.71 |
| EXPENDITURE ON GRNTS, SUBSIDIES ETC. | 22 | - | - |
| INTEREST | 23 | - | - |
| DEPRECIATION | 8 | 10,19,41,227.00 | 10,83,13,152.00 |
| TOTAL (B) | | 63,00,47,605.86 | 60,82,03,352.71 |
| BALANCE BEING SURPLUS/(DEFICIT) CARRIED TO | | | |
| CORPUS/CAPITAL FUND | | (7,59,54,399.56) | (8,69,86,782.32) |
| SIGNIFICANT ACCOUNTING POLICIES | 24 | | |
| CONTINGENT LIABILITIES AND NOTES ON ACCOUNTS | 25 | | |

The schedules referred to above form an integral part of the Income & Expenditure Account.

As per our report of even date.

Date: 24th June, 2025

Place: Pune

OFFICER 'C' ACCOUNTS

NCCS

वैभव अ. अरगडे

Vaibhav A. Argade
अधिकारी 'ग' (लखा)

Officer "C" (Accounts)

रा.को.वि.के./NCCS Pune-411007



DIRECTOR (ADDL. CHARGE)

NCCS

निदेशक(अतिरिक्त प्रभार)
राष्ट्रीय कोशिका विज्ञान केन्द्र, पुणे

Director (Addl. Charge)
National Centre for Cell Science, Pune



NITIN MULIK
PARTNER

M.NO.165937

Date: 24th June, 2025

Place: Pune

UDIN:25165937BMLZMF2606

NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007

RECEIPTS AND PAYMENTS FOR THE YEAR ENDED 31.03.2025

| Receipts | 2024-25 | Payments | 2024-25 | Amount (Rs.) |
|--|-----------------|--------------------------|---|--------------------------|
| Opening Balance | | 31,16,99,566.33 | Current Liabilities | |
| Bank Accounts | | | Hostel Charges Recovery-Payable | 71,250.00 |
| Bank of India - CSR 8574 | 40,09,412.54 | | Medical Insurance -Payable | 2,09,702.00 |
| NCCS Employee Welfare Current A/c 0538 | 24,47,907.55 | | PAYABLE | 16,110.00 |
| NCCS Bank Accounts | | | Duties & Taxes | |
| Bank of India - 4911 | 7,35,14,308.03 | | Salary - P.Tax Payable | 4,39,475.00 |
| STATE BANK OF INDIA | 2,31,39,550.87 | | TDS RECEIVABLE | 95,762.00 |
| Project Bank Account | | | GST | 53,19,284.00 |
| Bank of India 4912 | 19,34,66,950.91 | | TDS | 3,55,25,543.00 |
| BANK OF INDIA (FOR SERB) -8403 | 1,50,71,436.43 | | Sundry Creditors | 68,13,76,137.82 |
| Cash-in-hand | 50,000.00 | | EMD | 16,49,970.00 |
| Current Liabilities | | 7,38,493.00 | PBG | 60,871.00 |
| Duties & Taxes | | | Salary Payable | 18,06,93,512.00 |
| TCS Scrap CGST 0.5 % | 5,193.00 | | Security Deposit | 3,04,175.00 |
| TCS Scrap SGST 0.5 % | 5,193.00 | | Fixed Assets | 1,46,956.00 |
| Staff Welfare Fund | 1,52,107.00 | | Equipments | 1,46,956.00 |
| Student - Caution Money | 5,76,000.00 | | Current Assets | 30,39,912.00 |
| Current Assets | | 2,88,66,331.84 | Loans & Advances (Asset) | 30,39,912.00 |
| Sundry Debtors | 2,88,66,331.84 | | CORPUS/CAPITAL FUND | 53,82,465.00 |
| Suspense A/c | | 48,000.00 | Corpus/Capital Fund | 53,82,465.00 |
| Suspense NCCS A/c | 48,000.00 | | Earmarked Fund | 44,83,84,341.11 |
| Sales Accounts | | 21,240.00 | ESTABLISHMENT EXPENSES | 4,12,00,766.00 |
| INCOME FROM SALES/SERVICE | 21,240.00 | | Salaries | 4,12,00,766.00 |
| Indirect Incomes | | 29,35,493.00 | OTHER ADMINISTRATIVE EXPENSES | 1,32,70,675.69 |
| Conti-MIS INCOME | 20.00 | | Bank Charges | 51,647.17 |
| Interest Earned | 28,17,750.00 | | Professional Expenses for R & D | 14,26,937.66 |
| Interest Earned on Covid Testing Receipts A/c 8574 | 1,17,723.00 | | Rent Rates and Taxes | 25,528.00 |
| Indirect Expenses | | 3,971.08 | Rounded Off GST | 79.00 |
| Fund Transfer | 3,971.08 | | Consumables | 57,87,259.62 |
| Academic Other Income | | 28,14,713.00 | Contingencies | 31,79,448.24 |
| Academic Income | 1,500.00 | | TA-DA | 27,99,776.00 |
| Hostel Charges Recovery | 12,23,313.00 | | PROVISION | 7,30,10,013.00 |
| Ph.D Fees | 15,89,900.00 | | Provision for Leave Encashment & Gratuity | 1,28,49,633.00 |
| CORPUS/CAPITAL FUND | | 32,45,00,000.00 | PROVISION FOR WORKS ON CONTRAC | 6,01,60,380.00 |
| Corpus/Capital Fund | 32,45,00,000.00 | | Closing Balance | 31,99,02,495.99 |
| Earmarked Fund | | 61,12,97,392.36 | Bank Accounts | |
| GRANTS/SUBSIDIES | | 52,71,05,529.00 | Bank of India - CSR 8574 | 41,27,135.54 |
| Grant In Aid General | 25,89,02,690.00 | | NCCS Employee Welfare Current A/c | 25,25,814.55 |
| Grant In Aid Salary | 26,82,02,839.00 | | NCCS Bank Accounts | |
| OTHER ADMINISTRATIVE EXPENSES | | 68,687.00 | Bank of India - 4911 | 8,47,07,264.55 |
| Electricity & Power | 59,645.00 | | STATE BANK OF INDIA | 4,50,41,074.87 |
| PMC Water Charges | 9,042.00 | | Project Bank Account | |
| | | | Bank Of India 4912 | 16,85,12,235.30 |
| | | | BANK OF INDIA (FOR SERB) -84 | 1,49,88,971.18 |
| - Total | | 1,81,00,99,416.61 | Total | 1,81,00,99,416.61 |

Date: 24th June,2025

Place: Pune


OFFICER 'C' ACCOUNTS
NCCS

वैभव अ. अरगडे
Vaibhav A. Argade
अधिकारी 'ग' (लेखा)
Officer "C" (Accounts)
रा.को.वि.के./NCCS Pune-411007



DIRECTOR (ADDL. CHARGE)
NCCS

निदेशक(अतिरिक्त प्रभार)
राष्ट्रीय कोशिका विज्ञान केन्द्र, पुणे
Director (Addl. Charge)
National Centre for Cell Science, Pune



NITIN MULIK
PARTNER
M.NO.165937

Date: 24th June,2025
Place: Pune
UDIN:25165937BMLZMF2606
AC - 7



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE 1 - CORPUS/CAPITAL FUND

(Amount-Rs.)

| Particulars | 31.03.2025 | 31.03.2024 |
|--|--------------------------|--------------------------|
| SCHEDULE 1- CORPUS/CAPITAL FUND: | | |
| Balance at the beginning of the year | 1,15,09,23,918.36 | 97,93,96,833.68 |
| Less:(Deduct) : Balance of net income /(expenditure)/Refund through Bharatkosh | - | 1,84,94,000.00 |
| Deduct : Capital grants written off | - | - |
| Less: Deduction from TSA Account [Note: A (6) (v) Accounting Significant Policies] | 53,82,465.00 | 2,29,92,133.00 |
| | 1,14,55,41,453.36 | 93,79,10,700.68 |
| | | |
| Add : Contribution towards Capital Fund | 32,45,00,000.00 | 30,00,00,000.00 |
| Add : General Reserve | - | - |
| | 1,47,00,41,453.36 | 1,23,79,10,700.68 |
| | | |
| Add/(Deduct) : Bal. Of net income/(expenditure) transferred from the Income and Expenditure A/c. | (7,59,54,399.56) | (8,69,86,782.32) |
| | | |
| BALANCE AS AT THE YEAR - END | 1,39,40,87,053.80 | 1,15,09,23,918.36 |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE 2 -GENERAL RESERVE

| Particulars | 31.03.2025 | 31.03.2024 | Amount (Rs.) |
|---------------------|------------|------------|---------------|
| Capital Reserve | - | - | - |
| Revaluation Reserve | - | - | - |
| Special Reserve | - | - | - |
| General Reserve | - | - | - |
| Grand Total | - | - | - |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE-3 EARMARKED/ENDOWMENT FUND

(Amount-Rs.)

| No. | Name of the Project & P.I. | Opening | Grants | Additions | Interest & | Total | | | | | Closing |
|-----|---|------------------|-----------------|----------------|----------------|------------------|---------------------|-----------------|----------------|-----------------|------------------|
| | | Balance | Re-assigned | Grant. Recd. | Other Receipts | | Deduction from ZBSA | Capital | Revenue | Total | Balance |
| 1 | DBT-0150 (BRD Scheme) | 86,16,615.38 | 6,74,20,952.36 | 1,56,02,099.00 | 27,92,329.00 | 9,44,40,829.74 | 6,29,50,005.12 | 9,77,762.00 | 2,87,43,418.51 | 9,26,80,019.63 | 17,60,810.11 |
| 2 | DBT-0155 (IED Scheme) PUNE BIOCLUSTER-DR. SHEKHAR MANDE | 1,93,101.00 | 21,69,01,090.92 | - | - | 21,70,94,191.92 | 9,78,50,843.92 | 11,88,92,487.10 | 3,50,860.90 | 21,70,94,191.92 | - |
| 3 | DBT-4306 (Bio-RIDE Scheme) | - | - | 51,40,817.00 | - | 51,40,817.00 | 4,31,034.00 | 10,34,251.00 | 36,75,532.00 | 51,40,817.00 | - |
| 4 | AB/MW/BIOCARE/07/9813-AMRUTA BARHANPURKAR | (2,88,776.00) | - | - | - | (2,88,776.00) | - | - | - | - | (2,88,776.00) |
| 5 | AC/BIRAC/COVID-0032-DR. AKANKSHA CHATURVEDI | 40,851.00 | - | - | 1,508.00 | 42,359.00 | - | - | 42,359.00 | 42,359.00 | - |
| 6 | AC/SERB/CRG/004981-DR. AKANKSHA CHATURVEDI | 2,97,114.78 | - | - | 9,806.00 | 3,06,920.78 | - | - | - | - | 3,06,920.78 |
| 7 | AC/PADMAVATI VENKATESWARA FOUNDATION - DR CHATURVEDI | 32,70,856.00 | - | 44,13,032.00 | 1,20,359.00 | 78,04,247.00 | - | 2,26,735.00 | 42,28,717.00 | 44,55,452.00 | 33,48,795.00 |
| 8 | AC/SERB/IPA/000148-DR. AKANKSHA CHATURVEDI | 10,72,614.00 | - | - | 42,483.00 | 11,15,097.00 | - | - | 6,48,600.00 | 6,48,600.00 | 4,66,497.00 |
| 9 | AM/ICMR/TRAVEL FELLOWSHIP-DR. MAJUMDAR | 9,48,900.00 | - | - | - | 9,48,900.00 | - | - | 7,49,286.00 | 7,49,286.00 | 1,99,614.00 |
| 10 | AM/IFCPAR-DR. MAJUMDAR | 28,60,843.00 | - | 21,40,925.00 | 74,830.00 | 50,76,598.00 | - | 4,97,871.00 | 16,39,153.12 | 21,37,024.12 | 29,39,573.88 |
| 11 | AM/SERB/003130-DR. MAJUMDAR | 3,78,989.92 | - | 15,00,000.00 | 28,970.00 | 19,07,959.92 | - | - | 13,97,587.90 | 13,97,587.90 | 5,10,372.02 |
| 12 | AS/SERB/001054-DR. SAHU | - | - | 22,61,660.00 | 28,869.00 | 22,90,529.00 | - | - | 2,40,142.00 | 2,40,142.00 | 20,50,387.00 |
| 13 | AS/IGSTC WORKSHOP-DR. AVINASH SHARMA | - | - | 15,56,000.00 | - | 15,56,000.00 | - | - | 15,56,000.00 | 15,56,000.00 | - |
| 14 | AS/MoES/24-25-DR. AVINASH SHARMA | - | - | 68,66,992.00 | 60,729.00 | 69,27,721.00 | - | 10,81,889.00 | 36,51,282.00 | 47,33,171.00 | 21,94,550.00 |
| 15 | AS/SERB/000126-DR. AVINASH SHARMA | 68614 | - | 10,00,000.00 | 12,293.00 | 10,80,907.00 | - | - | 9,84,950.00 | 9,84,950.00 | 95,957.00 |
| 16 | AS/SERB/JCB/000020-DR. A K SAHU | 13,38,767.00 | - | 6,00,000.00 | 64,173.00 | 20,02,940.00 | - | - | 7,86,127.00 | 7,86,127.00 | 12,16,813.00 |
| 17 | AY/KR-03/NMPB-IV-DR. AMIT YADAV | 8,498.00 | 94,050.00 | - | - | 1,02,548.00 | 43,210.00 | - | 50,840.00 | 94,050.00 | 8,498.00 |
| 18 | BIVALKAR/WOS-A/LS/2016-DR. BIVALKAR | (1,60,453.00) | - | - | - | (1,60,453.00) | - | - | - | - | (1,60,453.00) |
| 19 | BS/SERB/JCB-DR. SAHA | 1,81,306.00 | - | - | 7,844.00 | 1,89,150.00 | - | - | 1,89,150.00 | 1,89,150.00 | - |
| 20 | CSIR | (1,96,82,864.05) | - | - | - | (1,96,82,864.05) | - | - | - | - | (1,96,82,864.05) |
| 21 | CSIR-RA FELLOWSHIP | (13,25,946.00) | - | - | - | (13,25,946.00) | - | - | - | - | (13,25,946.00) |
| 22 | DBT FELLOWSHIP | 46,05,133.24 | - | 1,17,92,415.00 | 2,02,658.00 | 1,66,00,206.24 | - | - | 1,27,91,773.20 | 1,27,91,773.20 | 38,08,433.04 |
| 23 | DBT - PDF PROGRAMME | 2,23,760.00 | - | - | 8,257.00 | 2,32,017.00 | - | - | - | - | 2,32,017.00 |
| 24 | GL/BT/03/IYBA-DR. LAL | (5,62,237.00) | - | - | - | (5,62,237.00) | - | - | - | - | (5,62,237.00) |
| 25 | SM/BT/NEW INDIGO/18-DR. MANDE | (6,59,959.00) | - | - | - | (6,59,959.00) | - | - | - | - | (6,59,959.00) |
| 26 | SM/BT/PR-3260/BRB/2012-17 | 6,92,740.00 | - | - | 25,563.00 | 7,18,303.00 | - | - | - | - | 7,18,303.00 |
| 27 | DBT-RA FELLOWSHIP | 1,79,438.39 | - | 9,35,645.00 | 9,796.00 | 11,24,879.39 | - | - | 8,43,063.00 | 8,43,063.00 | 2,81,816.39 |
| 28 | DBT TWAS FELLOWSHIP | 4,12,081.00 | - | 72,000.00 | 8,421.00 | 4,92,502.00 | - | - | 4,12,767.00 | 4,12,767.00 | 79,735.00 |
| 29 | DR. REDDY'S LAB. TECHNICAL SERVICES - DR. DHOTRE | - | - | 29,88,788.96 | 56,253.00 | 30,45,041.96 | - | - | 28,64,340.96 | 28,64,340.96 | 1,80,701.00 |
| 30 | DM/SERB/005348-DR. MITRA | - | - | 20,99,260.00 | 53,063.00 | 21,52,323.00 | - | - | 6,96,414.00 | 6,96,414.00 | 14,55,909.00 |
| 31 | DP/PACER-POP/BS-01-DR. DHIRAJ PAUL | 1,39,191.83 | - | - | 3,607.00 | 1,42,798.83 | - | - | 1,42,798.83 | 1,42,798.83 | - |
| 32 | DS/ICMR-2020-3076/SCR-DR. DEEPA | 35,337.95 | - | - | 1,650.00 | 36,987.95 | - | - | - | - | 36,987.95 |
| 33 | DS/SERB/CRG/002728-DR. DEEPA | 8,55,024.00 | - | 10,00,000.00 | 27,964.00 | 18,82,988.00 | - | - | 16,61,127.00 | 16,61,127.00 | 2,21,861.00 |
| 34 | DST INSPIRE FELLOWSHIP | 2,44,338.00 | 3,71,306.00 | 23,28,637.00 | 30,031.00 | 29,74,312.00 | 10,55,713.00 | - | 16,44,230.00 | 26,99,943.00 | 2,74,369.00 |
| 35 | DS/WELLCOMETRUST-DR. DEEPA | (4,91,460.00) | - | - | - | (4,91,460.00) | - | - | - | - | (4,91,460.00) |
| 36 | EMBO CONFERENCE (FEB.25) - DR. MAJUMDAR | - | - | 11,52,746.00 | - | 11,52,746.00 | - | - | 7,42,403.00 | 7,42,403.00 | 4,10,343.00 |
| 37 | EMBO CONFERENCE IN KIDNEY DISEASES | - | - | - | - | - | - | - | - | - | - |
| 38 | GD/CRG/2019-005587 - DR. GAURAV DAS | 1,05,728.43 | - | - | 4,564.00 | 1,10,292.43 | - | - | PUNE | 7,42,403.00 | 1,10,292.43 |



SCHEDULE-3 EARMARKED/ENDOWMENT FUND

(Amount-Rs.)

| No. | Name of the Project & P.I. | Opening | Grants | Additions | Interest & | Total | | | | | Closing |
|-----|--|-----------------|-------------|----------------|----------------|-----------------|---------------------|----------------|---------------|----------------|----------------|
| | | Balance | Re-assigned | Grant. Recd. | Other Receipts | | Deduction from ZBSA | Capital | Revenue | Total | Balance |
| 39 | GD/IISER-EMSTAR-DR. GAURAV DAS | - | - | 25,50,480.00 | 41,330.00 | 25,91,810.00 | - | - | 10,17,079.00 | 10,17,079.00 | 15,74,731.00 |
| 40 | GD/SB/S2/RJN-048/2017-DR. GAURAV DAS | 44,337.00 | - | - | - | 44,337.00 | - | - | 44,337.00 | 44,337.00 | - |
| 41 | GK/DST/IMRCD/INNO-INDIGO-DR. KUNDU | 2,23,717.00 | - | - | 8,256.00 | 2,31,973.00 | - | - | - | - | 2,31,973.00 |
| 42 | GK/SERB/002298-DR. KUNDU | 2,55,409.38 | - | - | - | 2,55,409.38 | - | - | 2,55,409.38 | 2,55,409.38 | - |
| 43 | GK/SR/SO/HS-70-DR. KUNDU | (3,32,350.00) | - | - | - | (3,32,350.00) | - | - | - | - | (3,32,350.00) |
| 44 | GL/DST/SJF/LSA-01-DR. LAL | 2,92,932.33 | - | - | 5,639.00 | 2,98,571.33 | - | - | 3,15,687.00 | 3,15,687.00 | (17,115.67) |
| 45 | GL/KEMHRC-DR. LAL | 6,20,346.20 | - | - | 21,292.00 | 6,41,638.20 | - | - | 1,76,736.00 | 1,76,736.00 | 4,64,902.20 |
| 46 | GL/KEMHRC-II-DR. LAL | 44,42,569.12 | - | - | 1,59,160.00 | 46,01,729.12 | - | - | 2,72,802.00 | 2,72,802.00 | 43,28,927.12 |
| 47 | GL/SERB/CRG/007108 (NEW)-DR. LAL | 10,07,838.56 | - | - | 37,687.00 | 10,45,525.56 | - | - | 7,51,143.00 | 7,51,143.00 | 2,94,382.56 |
| 48 | GM/NASI PLATINUM JUBILEE CHAIR-DR. MISHRA | 1,70,245.16 | - | - | 6,239.00 | 1,76,484.16 | - | - | - | - | 1,76,484.16 |
| 49 | HUMAN MICROBIOME AWARENESS-DR. DHIRAJ DHOTRE | 1,00,000.00 | - | - | - | 1,00,000.00 | - | - | 1,00,000.00 | 1,00,000.00 | - |
| 50 | ICMR | (9,59,320.35) | - | 40,45,505.00 | 78,118.00 | 31,64,302.65 | - | - | 39,36,266.00 | 39,36,266.00 | (7,71,963.35) |
| 51 | INSPIRE FACULTY AWARD-PRIYANKA DUTTA | 1,34,615.00 | - | - | 4,964.00 | 1,39,579.00 | - | - | - | - | 1,39,579.00 |
| 52 | INTERNATIONAL TRAVEL - MR. AKSHAY LONARE | - | - | 1,03,935.00 | - | 1,03,935.00 | - | - | 1,03,935.00 | 1,03,935.00 | - |
| 53 | INTRAMURAL PROJECT-IM-001 | (24,368.36) | - | - | - | (24,368.36) | - | - | (24,368.36) | (24,368.36) | (0.00) |
| 54 | INTRAMURAL PROJECT-IM-002 | (4,48,468.68) | - | - | - | (4,48,468.68) | - | - | (4,48,468.68) | (4,48,468.68) | - |
| 55 | JJ/IISER-EMSTAR-DR. JOSEPH | - | - | 21,25,400.00 | 22,994.00 | 21,48,394.00 | - | - | -18,53,378.00 | 18,53,378.00 | 2,95,016.00 |
| 56 | JJ/SERB/000352-DR. JOSEPH | 16,91,394.00 | - | 10,00,000.00 | 32,412.00 | 27,23,806.00 | - | - | 24,65,577.00 | 24,65,577.00 | 2,58,229.00 |
| 57 | JK/DST/FRG/DAAD/P-18-DR. JANESH | 2,59,998.00 | - | - | 9,594.00 | 2,69,592.00 | - | - | 2,69,592.00 | 2,69,592.00 | - |
| 58 | JS/WELLCOME - DR. JYOTI SINGH | 10,70,382.42 | - | - | - | 10,70,382.42 | - | - | 10,70,382.42 | 10,70,382.42 | - |
| 59 | JUILEE/NASI PLATINUM JUBILEE CHAIR | 40,247.00 | - | - | 1,485.00 | 41,732.00 | - | - | 41,732.00 | 41,732.00 | - |
| 60 | LL/DAE/37B/BRNS-DR. LIMAYE | (48,247.00) | - | - | - | (48,247.00) | - | - | - | - | (48,247.00) |
| 61 | LL/JAI RESEARCH FOUNDATION-DR. LIMAYE | (25,46,806.00) | - | - | - | (25,46,806.00) | - | - | - | - | (25,46,806.00) |
| 62 | MB/SERB/005264-DR. BHAT | 6,94,821.00 | - | 9,00,000.00 | 22,211.00 | 16,17,032.00 | - | - | 8,68,843.00 | 8,68,843.00 | 7,48,189.00 |
| 63 | MS/ICMR-DR. MANAS SANTRA | 2,33,406.00 | - | 37,00,538.00 | 9,682.00 | 39,43,626.00 | - | - | 29,67,851.79 | 29,67,851.79 | 9,75,774.21 |
| 64 | MS/CSIR/37/(1655)/15/EMR-II-DR. MANAS SANTRA | 43,755.00 | - | - | 1,614.00 | 45,369.00 | - | - | 45,369.00 | 45,369.00 | - |
| 65 | MS/LADY TATA FELLOWSHIP-DR. MANAS SANTRA | 8,593.00 | - | - | 319.00 | 8,912.00 | - | - | 8,912.00 | 8,912.00 | - |
| 66 | MS/SERB/CRG/005433-DR. MANAS SANTRA | 3,32,291.68 | - | - | 14,376.00 | 3,46,667.68 | - | - | - | - | 3,46,667.68 |
| 67 | MW/BHU-DR. WANI | 23,069.00 | - | - | 851.00 | 23,920.00 | - | - | 23,920.00 | 23,920.00 | - |
| 68 | MW/SERB/004441-DR. WANI | 2,26,627.37 | - | - | 9,829.00 | 2,36,456.37 | - | - | - | - | 2,36,456.37 |
| 69 | NAS/141/7/2014-15-DR. RANI LEKHA | (2,34,000.00) | - | - | - | (2,34,000.00) | - | - | - | - | (2,34,000.00) |
| 70 | OP/EMR/2016/006589-DR. OM PRAKASH | 28,299.00 | - | - | 1,233.00 | 29,532.00 | - | - | - | - | 29,532.00 |
| 71 | PA/DST-INSPIRE FACULTY-DR. PRASAD ABNAVE | 2,875.00 | - | 8,19,327.00 | - | 8,22,202.00 | 6,49,999.00 | - | 1,69,328.00 | 8,19,327.00 | 2,875.00 |
| 72 | PD/SERB/CRG/001727-DR. PRIYANKA DUTTA | 23,981.00 | - | - | 1,040.00 | 25,021.00 | - | - | 25,021.00 | 25,021.00 | - |
| 73 | PD/SB/SRS/2022-23/108/LS-DR. PRIYANKA DUTTA | 95,108.00 | - | - | - | 95,108.00 | - | - | 95,108.00 | 95,108.00 | - |
| 74 | PN/BT/NBM/0166/04/19/BIRAC-DR. NAGVENKAR | 12,92,31,544.36 | - | - | 45,83,888.00 | 13,38,15,432.36 | - | 3,76,11,440.00 | 39,46,136.00 | 4,15,57,576.00 | 9,22,57,856.36 |
| 75 | PROJECT OVERHEADS | 3,71,39,523.96 | - | 1,26,77,696.27 | - | 4,98,17,220.23 | - | - | 6,22,201.52 | 6,22,201.52 | 4,91,95,018.71 |
| 76 | PS/ICMR/53/6/BM-DR. PADMA SHAstry | (6,60,992.00) | - | - | - | (6,60,992.00) | - | - | - | - | (6,60,992.00) |
| 77 | RC/SB/SO/BB-0030/13-16-DR. RADHA CHAUHAN | (2,46,623.00) | - | - | - | (2,46,623.00) | - | - | - | - | (2,46,623.00) |
| 78 | SA/BT/RLF/RE-ENTRY-DR. SUSMITHA | 5,06,281.00 | - | - | 12,300.00 | 5,18,581.00 | - | - | 4,97,319.00 | 4,97,319.00 | 21,262.00 |
| 79 | SB/CRG/2019/001157 - DR. BAPAT | 4,19,171.07 | - | - | 18,176.00 | 4,37,347.07 | - | - | - | - | 4,37,347.07 |
| 80 | SB/ADHOC-BMMS/168/ICMR- DR. BAPAT | 5,78,122.00 | - | 23,74,752.00 | 48,588.00 | 30,01,462.00 | - | - | 25,20,442.95 | 25,20,442.95 | 4,81,019.05 |
| 81 | SC/CSIR/37(1572)-DR.SAMIT | (2,27,473.00) | - | - | - | (2,27,473.00) | - | - | - | - | (2,27,473.00) |
| 82 | SERB PDF | 10,09,990.00 | - | - | 37,290.00 | 10,47,280.00 | - | - | - | - | 10,47,280.00 |
| 83 | SK/SERB/000732-DR. SANTOSH KUMAR | 3,17,568.30 | - | 5,50,000.00 | 20,274.00 | 8,87,842.30 | - | - | 6,20,022.00 | 6,20,022.00 | 2,67,820.30 |



SCHEDULE-3 EARMARKED/ENDOWMENT FUND

(Amount-Rs.)

| No. | Name of the Project & P.I. | Opening | Grants | Additions | Interest & | Total | | | | | Closing |
|-----|---|-----------------|-----------------|-----------------|----------------|-----------------|---------------------|-----------------|-----------------|-----------------|-----------------|
| | | Balance | Re-assigned | Grant. Recd. | Other Receipts | | Deduction from ZBSA | Capital | Revenue | Total | Balance |
| 84 | SK/WELLCOME-DR. SANTOSH KUMAR | 56,88,397.00 | - | 1,04,95,600.00 | 3,26,692.00 | 1,65,10,689.00 | - | 1,04,02,677.00 | 49,43,247.00 | 1,53,45,924.00 | 11,64,765.00 |
| 85 | SM/DST/INT/RFBR/P-89-DR. MANDE | (2,38,142.00) | - | - | - | (2,38,142.00) | - | - | - | - | (2,38,142.00) |
| 86 | SM/DST/SPAIN/P-26/23.7.12-22.7.15-DR. MANDE | (4,30,348.00) | - | - | - | (4,30,348.00) | - | - | - | - | (4,30,348.00) |
| 87 | SM/SB/S2/JCB FELLOWSHIP-01/2023-DR. MANDE | 3,90,323.00 | - | 13,00,000.00 | 21,602.00 | 17,11,925.00 | - | - | 15,61,036.00 | 15,61,036.00 | 1,50,889.00 |
| 88 | SM/WELLCOME-DR. SANJUKTA MUKHERJEE | 28,09,373.00 | - | 86,43,360.00 | 3,36,335.00 | 1,17,89,068.00 | - | 4,65,638.00 | 25,34,224.25 | 29,99,862.25 | 87,89,205.75 |
| 89 | SR/DST/IMRC/INNO-INDIGO-DR. SRIKANTH | (2,25,736.00) | - | - | - | (2,25,736.00) | - | - | - | - | (2,25,736.00) |
| 90 | SS/58/39/2020/PHS/(BMS)/ICMR-DR. SHAILAZA SINGH | 59,014.00 | - | 4,25,731.00 | 4,757.00 | 4,89,502.00 | - | - | 4,37,334.00 | 4,37,334.00 | 52,168.00 |
| 91 | STRUCTURAL BASED DRUG DESIGNING (SBDD) | (1,57,063.00) | - | - | - | (1,57,063.00) | - | - | (1,57,063.00) | (1,57,063.00) | - |
| 92 | STUDENT'S SYMPOSIUM | - | - | 2,44,319.00 | - | 2,44,319.00 | - | - | 2,44,319.00 | 2,44,319.00 | - |
| 93 | UGC | (71,23,922.50) | - | - | - | (71,23,922.50) | - | - | - | - | (71,23,922.50) |
| 94 | VK/DAE/PR-37B/BRNS-DR.KALE | (2,47,647.00) | - | - | - | (2,47,647.00) | - | - | - | - | (2,47,647.00) |
| 95 | VT/SERB/004159-DR. TRIPATHI | 5,58,797.07 | - | - | 24,236.00 | 5,83,033.07 | - | - | - | - | 5,83,033.07 |
| 96 | WORKSHOP ON H.M.D.-DR. SHAILAZA SINGH | 35,170.00 | - | - | - | 35,170.00 | - | - | 35,170.00 | 35,170.00 | - |
| 97 | WORKSHOP ON MMD & NB-DR. SHAILAZA SINGH | - | - | 1,47,035.00 | - | 1,47,035.00 | - | - | 1,47,035.00 | 1,47,035.00 | - |
| 98 | WORKSHOP ON P N & B-DR. SHAILAZA SINGH | - | - | 16,357.00 | - | 16,357.00 | - | - | 16,357.00 | 16,357.00 | - |
| 99 | YS/BIRAC-DR. SHOUCHE | 1,11,923.00 | - | - | 4,414.00 | 1,16,337.00 | - | - | - | - | 1,16,337.00 |
| 100 | YS/ES/PO/SEISMO/1(361)/2019 | 45,611.00 | - | - | 1,684.00 | 47,295.00 | - | - | 47,295.00 | 47,295.00 | - |
| 101 | YS/ICMR/236-DR. SHOUCHE | 3,86,343.00 | - | 600.00 | 10,650.00 | 3,97,593.00 | - | - | 3,97,593.00 | 3,97,593.00 | - |
| 102 | INDO-UK CONFERENCE-DR. WANI | (4,15,908.00) | - | - | - | (4,15,908.00) | - | - | - | - | (4,15,908.00) |
| 103 | MASSTRICH UNIV. PROJECT | (3,50,730.00) | - | - | - | (3,50,730.00) | - | - | - | - | (3,50,730.00) |
| 104 | Receivable | 1,55,644.00 | - | - | - | 1,55,644.00 | - | - | 1,55,644.00 | 1,55,644.00 | - |
| | Total | 18,01,89,655.96 | 28,47,87,399.28 | 11,55,71,652.23 | 96,17,231.00 | 59,01,74,772.47 | 16,29,80,805.04 | 17,11,90,750.10 | 10,57,06,806.69 | 43,98,87,195.83 | 15,02,87,576.64 |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE 4 - SECURED LOANS AND BORROWINGS

Amount (Rs.)

| Particulars | 31.03.2025 | 31.03.2024 |
|------------------------------------|------------|------------|
| 1. Central Government | - | - |
| 2. State Government (Specify) | - | - |
| 3. Financial Institutions | | |
| a) Term Loans | - | - |
| b) Interest accrued and due | - | - |
| 4. Banks: | | |
| a) Term Loans | - | - |
| - Interest accrued and due | - | - |
| b) Other Loans (Specify) | - | - |
| - Interest accrued and due | - | - |
| 5. Other Institutions and Agencies | - | - |
| 6. Debentures and Bonds | - | - |
| 7. Others (Specify) | - | - |
| Total | - | - |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE 5 - UNSECURED LOANS AND BORROWINGS

| Particulars | 31.03.2025 | Amount (Rs.) 31.03.2024 |
|------------------------------------|------------|-----------------------------|
| 1. Central Government | - | - |
| 2. State Government | - | - |
| 3. Financial Institutions | - | - |
| 4. Banks: | | |
| a) Term Loans | - | - |
| b) Other Loans | - | - |
| 5. Other Institutions and Agencies | - | - |
| 6. Debentures and Bonds | - | - |
| 7. Fixed Deposits | - | - |
| 8. Others | - | - |
| Total | - | - |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE 6- DEFERRED CREDIT LIABILITIES

| Particulars | Amount (Rs.) | |
|--|----------------------|-------------------|
| | 31.03.2025 | 31.03.2024 |
| a) Acceptance secured by hypothecation of capital equipment and other assets | - | - |
| b) Others | - | - |
| Total | - | - |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE 7 - CURRENT-LIABILITIES

Amount (Rs.)

| Particulars | 31.03.2025 | 31.03.2024 |
|---|-----------------------|-----------------------|
| Canteen Deposit | 10,000.00 | 10,000.00 |
| Earnest Money Deposit | 10,00,570.00 | 26,50,540.00 |
| Security Deposit | 64,87,036.00 | 21,92,806.00 |
| Security Deposit/ Caution Money | 47,38,001.00 | 41,62,001.00 |
| * M/s Shalaka Infra-Tech(I) Pvt. Ltd. | 15,55,516.00 | 15,55,516.00 |
| GST Payable | 10,25,686.96 | 6,98,277.00 |
| Tax Deducted at Source payable | 18,08,825.00 | - |
| GST TDS Payable | 29,22,303.00 | 6,92,439.00 |
| Sundry Creditor | 3,66,651.00 | 9,42,500.00 |
| Advance from Customers | 33,89,278.25 | 21,67,492.89 |
| Salary Profession Tax Payable | 48,600.00 | 47,375.00 |
| Performance Gurantee Deposit (PBG) | 8,22,350.00 | 8,83,221.00 |
| Salary- Employee Welfare Deduction | 41,77,552.00 | 32,43,143.00 |
| Salary Payable | 1,90,63,270.00 | 17,04,189.00 |
| Provision for Gratuity & Leave Encashment | 1,95,70,825.00 | 3,24,20,458.00 |
| Provision for Charity Commissioner | 41,04,068.00 | 35,64,314.00 |
| Provision of Auditors Fee | 1,49,600.00 | 1,49,600.00 |
| Payable | - | 16,110.00 |
| **Transport Allowance Recovery | 56,540.00 | 56,540.00 |
| Grand Total | 7,12,96,672.21 | 5,71,56,521.89 |

Note

*Amount kept on hold due to non-completion of work within contract period by the said Vendor.

** Transport Allowance Recovered of Rs. 56,540.00 from Dr. Krishnasastray as per C & AG Audit objection and kept under current liabilities, as the proposal of reconsideration is sent to Department of Biotechnology, New Delhi.



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE 8 - FIXED ASSETS

(Amount-Rs.)

| DESCRIPTION | Rate | GROSS BLOCK | | | | DEPRECIATION / AMORTIZATION | | | | NET BLOCK | |
|--|--------|----------------------------|---------------------------|---------------------------|--------------------------------|---------------------------------|---------------------------|---------------------------|--------------------------|----------------------------|-----------------------------|
| | | As at begining of the year | Additions during the year | Deduction during the year | Cost valuation at the year-end | As at the beginning of the year | Additions during the year | Deduction during the year | Total up to the Year-end | As at the Current year-end | As at the Previous year-end |
| A. FIXED ASSETS: | | | | | | | | | | | |
| 1. Lease Hold Land Baner | | 1,54,41,563.00 | - | - | 1,54,41,563.00 | 36,03,032.00 | 5,14,719.00 | - | 41,17,751.00 | 1,13,23,812.00 | 1,18,38,531.00 |
| a> Lease Hold Land - Baner | | | | | | | | | | | |
| 2. BUILDINGS: | 4.87% | | | | | | | | | | |
| a> Jopasana | | 60,26,554.30 | - | - | 60,26,554.30 | 40,68,263.00 | 95,369.00 | - | 41,63,632.00 | 18,62,922.00 | 19,58,291.00 |
| b> Jidnyasa | | 69,14,265.25 | 60,05,605.00 | - | 1,29,19,870.25 | 46,33,920.00 | 2,86,838.00 | - | 49,20,758.00 | 79,99,112.00 | 22,80,345.00 |
| c> University Campus | | 55,55,96,001.46 | 25,58,485.00 | - | 55,81,54,486.46 | 22,81,34,000.00 | 1,60,09,826.00 | - | 24,41,43,826.00 | 31,40,10,660.00 | 32,74,62,001.00 |
| d> Lease Hold Land - Baner - Compound Wall | | 17,48,412.00 | - | - | 17,48,412.00 | 2,49,772.00 | 72,984.00 | - | 3,22,756.00 | 14,25,656.00 | 14,98,640.00 |
| 3. Furniture & Fixtures | 25.89% | 7,43,51,310.73 | 43,220.00 | - | 7,43,94,530.73 | 6,88,82,311.00 | 14,27,114.00 | - | 7,03,09,425.00 | 40,85,106.00 | 54,69,000.00 |
| 4. Library Books | 18.10% | 10,48,14,127.25 | 9,23,813.00 | - | 10,57,37,940.25 | 9,34,46,983.00 | 22,00,779.00 | - | 9,56,47,762.00 | 1,00,90,178.00 | 1,13,67,144.00 |
| 5. Equipment | | | | | | | | | | | |
| a> Institute | 18.10% | 1,88,12,35,556.26 | 8,10,23,244.00 | - | 1,96,22,58,800.26 | 1,47,96,43,969.00 | 8,08,77,211.00 | - | 1,56,05,21,180.00 | 40,17,37,620.00 | 40,15,91,587.00 |
| b> Fetal Liver project * | | 2,00,000.00 | - | - | 2,00,000.00 | 1,99,999.00 | - | - | 1,99,999.00 | 1.00 | 1.00 |
| 6. Vehicles * | | 13,11,895.00 | 11,61,289.00 | - | 24,73,184.00 | 13,11,894.00 | 4,56,387.00 | - | 17,68,281.00 | 7,04,903.00 | 1.00 |
| Total A | | 2,64,76,39,685.25 | 9,17,15,656.00 | - | 2,73,93,55,341.25 | 1,88,41,74,143.00 | 10,19,41,227.00 | - | 1,98,61,15,370.00 | 75,32,39,970.00 | 76,34,65,541.00 |
| B. Capital WIP | | | | | | | | | | | |
| a) WIP - Baner Building | | - | 22,65,30,412.00 | - | 22,65,30,412.00 | - | - | - | - | 22,65,30,412.00 | - |
| b) AHU & Chiller WIP | | - | 1,61,01,222.00 | - | 1,61,01,222.00 | - | - | - | - | 1,61,01,222.00 | - |
| c) Cooling Tower Central WIP | | - | 42,71,787.00 | - | 42,71,787.00 | - | - | - | - | 42,71,787.00 | - |
| d) Rooftop WIP | | - | 99,33,525.00 | - | 99,33,525.00 | - | - | - | - | 99,33,525.00 | - |
| Total B | | - | 25,68,36,946.00 | - | 25,68,36,946.00 | - | - | - | - | 25,68,36,946.00 | - |
| Total A + B | | 2,64,76,39,685.25 | 34,85,52,602.00 | - | 2,99,61,92,287.25 | 1,88,41,74,143.00 | 10,19,41,227.00 | - | 1,98,61,15,370.00 | 1,01,00,76,916.00 | 76,34,65,541.00 |

Note: The aforesaid expenditure is incurred out of Govt. Grants, disposal of which is subject to conditions attached to these Grants.

* As the useful lifes of Fetal Liver are expired, both are recorded at nominal value of Rs.1.00.



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE 9 - INVESTMENTS FROM EARMARKED/ ENDOWMENT FUNDS

| Particulars | Amount (Rs.) | |
|------------------------------------|----------------------|-------------------|
| | 31.03.2025 | 31.03.2024 |
| 1. In Government Securities | - | - |
| 2. Other approved Securities | - | - |
| 3. Shares | - | - |
| 4. Debentures and Bonds | - | - |
| 5. Subsidiaries and Joint Ventures | - | - |
| 6. Others | - | - |
| Total | - | - |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE 10 - INVESTMENTS - OTHERS

Amount (Rs.)

| Particulars | 31.03.2025 | 31.03.2024 |
|------------------------------------|-------------------|-------------------|
| 1. In Government Securities | - | - |
| 2. Other approved Securities | - | - |
| 3. Shares | - | - |
| 4. Debentures and Bonds | - | - |
| 5. Subsidiaries and Joint Ventures | - | - |
| 6. Others | - | - |
| Total | - | - |






NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF BALANCE SHEET AS ON 31.03.2025

SCHEDULE 11- CURRENT ASSETS, LOAN AND ADVANCES

| Particulars | 31.03.2025 | 31.03.2024 | Amount (Rs.) |
|--|------------------------|------------------------|---------------|
| CURRENT ASSET | | | |
| Cash-in-hand | - | 50,000.00 | |
| SAVING ACCOUNTS | | | |
| Bank of India - 4911 | 8,47,07,264.55 | 7,35,14,308.03 | |
| Bank of India - 4912 | 16,85,12,235.30 | 19,34,66,950.91 | |
| State Bank Of India | 4,50,41,074.87 | 2,31,39,550.87 | |
| Bank of India-SERB 8403 | 1,49,88,971.18 | 1,50,71,436.43 | |
| Bank of India - 8574 | 41,27,135.54 | 40,09,412.54 | |
| Bank of India - NCCS Employee Welfare A/c 0538 | 25,25,814.55 | 24,47,907.55 | |
| TOTAL (A) | 31,99,02,495.99 | 31,16,99,566.33 | |
| LOAN AND ADVANCES | | | |
| Advance-LTC | 4,49,057.00 | 3,47,960.00 | |
| Advance-TA/DA | 1,80,000.00 | 21,378.00 | |
| Staff Computer Advance | 2,326.00 | 12,402.00 | |
| Deposit for Compressor for AC Plant-Phase II | 37,80,000.00 | 38,29,000.00 | |
| Deposit for AC Plant-Phase II | 56,88,307.00 | 57,68,307.00 | |
| Deposit to DAE-University Campus-Phase I | 2,07,948.00 | 2,07,948.00 | |
| Equipment-Security Deposit | 38,663.60 | 38,663.60 | |
| Gas Deposit | 49,650.00 | 49,650.00 | |
| MSED Deposit | 87,39,500.00 | 73,12,600.00 | |
| MSED Deposit (Kothrud) | 10,33,962.00 | 10,61,547.00 | |
| Telephone Deposit | 1,21,701.00 | 1,21,701.00 | |
| TDS Receivable FY 2017-18 | 6,20,934.00 | 6,20,934.00 | |
| TDS Receivable FY 2018-19 | 8,08,568.00 | 8,08,568.00 | |
| TDS & TCS Receivable FY 2020-21 | 1,41,569.64 | 1,41,569.64 | |
| TDS & TCS Receivable FY 2021-22 | 94,963.17 | 94,963.17 | |
| TDS & TCS Receivable FY 2022-23 | 1,85,373.46 | 1,85,373.46 | |
| TDS & TCS Receivable FY 2023-24 | 1,06,595.01 | 1,06,595.01 | |
| TDS & TCS Receivable FY 2024-25 | 3,73,010.78 | - | |
| GST TDS Receivable 21-22 | 12,000.00 | 12,000.00 | |
| Advance -CPWD | 26,30,57,762.00 | 29,23,63,829.00 | |
| TOTAL (B) | 28,56,91,890.66 | 31,31,04,988.88 | |
| GRAND TOTAL | 60,55,94,386.65 | 62,40,04,955.21 | |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 12- INCOME FROM SALES/SERVICE

| Particulars | 2024-25 | 2023-24 | Amount (Rs.) |
|---|-----------------------|-----------------------|---------------|
| Cell Line Handling | 1,51,58,000.00 | 1,16,35,184.00 | |
| LC-MS/MS Proteome Analysis (Digested Samples) | - | 80,000.00 | |
| LC-MS/MS Proteome Analysis (Orbitrap MS/MS) | 5,46,000.00 | 4,15,000.00 | |
| FACS Analysis Charges | 1,05,000.00 | 51,000.00 | |
| Bio Imaging Facility | 1,32,700.00 | 76,000.00 | |
| Cell Line Authentication | 1,77,943.00 | 2,01,000.00 | |
| Plasmon Resonance Interactive Analysis Facility | - | 82,500.00 | |
| Mycoplasma Testing Charges | 19,800.00 | 21,600.00 | |
| Income from Protein Structure Prediction | - | 2,667.00 | |
| Grand Total | 1,61,39,443.00 | 1,25,64,951.00 | |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 13 - GRANTS/SUBSIDIES

Amount (Rs.)

| Particulars | 2024-25 | 2023-24 |
|--|------------------------|------------------------|
| GRANTS/SUBSIDIES | 55,35,00,000.00 | 50,00,00,000.00 |
| Less: Deduction from TSA Account [Note: A (6) (vi) Accounting Significant Policies] | 2,63,94,471.00 | 14,530.00 |
| Grand Total | 52,71,05,529.00 | 49,99,85,470.00 |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 14 - FEES/SUBSCRIPTIONS

Amount (Rs.)

| Particulars | 2024-25 | 2023-24 |
|--------------------|---------------------|---------------------|
| Tender Fees | 2,544.00 | 5,085.00 |
| Ph.D Fees | 19,50,900.00 | 17,10,064.00 |
| Application Fee | - | 5,695.00 |
| License Fee | 2,31,791.00 | 2,93,394.00 |
| Grand Total | 21,85,235.00 | 20,14,238.00 |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 15 - INCOME FROM INVESTMENTS

| Particulars | Amount (Rs.) | | | |
|--|--------------------------------|---------|---------------------|---------|
| | Investment from Earmarked Fund | | Investment - Others | |
| (Income on Investments from Earmarked/ Endowment Funds transferred to Funds) | 2024-25 | 2023-24 | 2024-25 | 2023-24 |
| 1. Interest | | | | |
| a) On Government Securities | - | - | - | - |
| b) Other Bonds/Debentures | - | - | - | - |
| 2. Dividends | | | | |
| a) On Shares | - | - | - | - |
| b) On Mutual Fund Securities | - | - | - | - |
| 3. Rents | - | - | - | - |
| 4. Others | - | - | - | - |
| Total | - | - | - | - |
| TRANSFERRED TO EARMARKED/ ENDOWMENT FUNDS | - | - | | |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 16- INCOME FROM ROYALTY, PUBLICATION ETC.

| Particulars | Amount (Rs.) | |
|------------------------|------------------|---------|
| | 2024-25 | 2023-24 |
| 1. Income from Royalty | 39,759.30 | - |
| Total | 39,759.30 | - |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 17 - INTEREST EARNED

| Particulars | 2024-25 | 2023-24 | Amount (Rs.) |
|---|---------------------|---------------------|---------------|
| Interest On Staff Computer Adv. | 52,733.00 | 48,290.00 | |
| Interest On Staff HBA | - | - | |
| Interest earned | 28,17,750.00 | 28,60,372.00 | |
| Interest on MSEB deposit | 4,93,723.00 | 3,78,587.00 | |
| Income from BCCT Workshop | 2,10,000.00 | 2,05,000.00 | |
| Interest earned on Covid Testing Receipts A/C No.8574 | 1,17,723.00 | 1,14,040.00 | |
| Grand Total | 36,91,929.00 | 36,06,289.00 | |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 18 - OTHER INCOME

Amount (Rs.)

| Particulars | 2024-25 | 2023-24 |
|------------------------------|---------------------|---------------------|
| Hostel Charges | 12,69,733.00 | 11,28,980.00 |
| Conti (Miscellaneous Income) | 2,75,350.00 | 9,684.39 |
| Receipts from Guest House | 4,31,811.00 | 3,16,776.00 |
| Sale of Scrap | 24,35,392.00 | 10,60,632.00 |
| Auditorium Charges | - | 1,04,746.00 |
| Income from Road Show | 2,70,000.00 | 1,65,000.00 |
| Income from Day Care | 2,25,025.00 | 2,59,804.00 |
| Income from Seminar Hall | 24,000.00 | - |
| Grand Total | 49,31,311.00 | 30,45,622.39 |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 19 - INCREASE/(DECREASE) IN STOCK OF FINISHED GOODS & WORK IN PROGRESS

| Particulars | Amount (Rs.) | |
|--------------------------------------|--------------|----------|
| | 2024-25 | 2023-24 |
| a) Closing Stock | | |
| - Finished Goods | - | - |
| - Work-in-progress | - | - |
| b) Less: Opening Stock | | |
| - Finished Goods | - | - |
| - Work-in-progress | - | - |
| NET INCREASE/(DECREASE) (a-b) | - | - |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 20 - ESTABLISHMENT EXPENSES

Amount (Rs.)

| Particulars | 2024-25 | 2023-24 |
|--------------------------------|------------------------|------------------------|
| Salaries | 24,33,56,762.00 | 22,93,10,748.00 |
| Contribution to Provident Fund | 1,12,33,021.00 | 1,03,36,113.00 |
| Contribution to NPS | 1,41,68,782.00 | 1,04,44,268.00 |
| Grand Total | 26,87,58,565.00 | 25,00,91,129.00 |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 21 - OTHER ADMINISTRATIVE EXPENSES

Amount (Rs.)

| Particulars | 2024-25 | 2023-24 |
|---|------------------------|------------------------|
| Consumables | 8,14,11,883.79 | 8,22,09,828.90 |
| Contingencies (as per attached details) | 3,63,75,801.24 | 2,92,63,878.20 |
| Auditors Remuneration | 1,49,600.00 | 1,49,600.00 |
| Work On Contract | 5,25,15,944.00 | 4,88,19,951.00 |
| Electricity and Power | 6,06,22,043.00 | 5,78,05,611.00 |
| Rent Rates and Taxes | 1,25,26,562.00 | 1,27,72,277.00 |
| PMC Water Charges | 30,71,857.00 | 25,25,136.00 |
| User Charges @5% trf to Staff Welfare A/c | 8,56,502.00 | 6,70,324.00 |
| TA-DA | 47,26,002.00 | 58,27,469.00 |
| Bank Charges | 51,720.17 | 27,224.45 |
| Fellowship-JGEEBILS | 52,56,138.00 | 65,18,454.00 |
| Professional Expenses for R & D | 17,83,760.66 | 32,09,318.16 |
| Grand Total | 25,93,47,813.86 | 24,97,99,071.71 |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 22 - EXPENDITURE ON GRANTS, SUBSIDIES ETC.

| Particulars | Amount (Rs.) | |
|--|---------------|----------|
| | 2024-25 | 2023-24 |
| a) Grants given to Institutions / Organisations | - | - |
| b) Subsidies given to Institutions / Organisations | - | - |
| TOTAL | - | - |



NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

SCHEDULE 23 - INTEREST

| Particulars | Amount (Rs.) | |
|--|---------------|----------|
| | 2024-25 | 2023-24 |
| a) On Fixed Loans | - | - |
| b) On Other Loans (including Bank Charges) | - | - |
| c) Others | - | - |
| TOTAL | - | - |



SCH. "24" : SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS FOR THE YEAR 2024-2025

National Centre for Cell Science ("NCCS") has been registered as a Trust under The Maharashtra Public Trust Act 1950 / Bombay Public Trust Act, 1950 on 31st October, 1988 and under the Societies Registration Act, 1860 on 26th August, 1988.

The principal activity of the trust is as follows:

- (a) To receive, identify ,maintain ,store ,grow and supply :
 - i) Animal and Human Cells/Cell cultures, cell line of both existing (typed) and newly developed.
 - ii) Tissues ,organs ,eggs (including fertilized) , and embryos.
 - iii) Hybrid cells including hybridomas.
 - iv) Unicellular obligate pathogens, parasites and vectors.
 - v) Plasmids, genes and genomic libraries.
- (b) Develop ,prepare ,quality control and supply culture media, other reagents and materials and cell products independently and in collaboration with industry and other organizations.
- (c) Research & Development in the above and cell culture related materials and products.
- (d) To establish and conduct post-graduate courses, workshops, seminars, symposia and training programmes in the related fields
- (e) To organize training programmes for technical personnel in Tissue Culture technology ,tissue banking cell products and related areas.
- (f) To serve as a National Reference Centre for Tissue Culture ,Tissue Banking ,Cell products and Data Bank etc. and to provide consultancy services to medical, Veterinary, Pharmaceutical institutions, public Health Services and Industries etc. in the country.
- (g) To provide and promote effective linkages on a continuous basis between various scientific and research agencies/laboratories and other organizations including industries working in the country.
- (h) To collaborate with foreign research institutions and laboratories and other international organizations in the areas relevant to the objectives of the facility.
- (i) To participate in such programmes as required in the country for the betterment of Society and advancement in science and technology.
- (j) To publish and disseminate information relating to results of research.
- (k) To establish affiliation with recognized universities and institutions of higher learning for the purpose of enabling research scholars to register for post-graduate degrees.
- (l) To establish ,maintain and manage laboratories, workshops, stores and other facilities for the efficient prosecution of scientific and technological research in animal tissue culture and related areas.
- (m) To create administrative, technical and other posts and scholarships and fellowships under the Facility and to make appointments there to accordance with the rules and regulations of the Facility.
- (n) To appoint and hire services or discharge/terminate the services of the personnel and to pay them in return for the services rendered to the Facility, Salaries, Wages, Gratuities, Provident Fund and other allowances or remunerations, honorarium in accordance with the rules and regulations of the facility.
- (o) To accept and undertake the management of any endowment or trust fund or donation , to in furtherance the objectives of the Facility.
- (p) To receive grants-in-aid in cash or in other forms from the Government of India, State Governments, Charitable Institutions/Trusts, individuals and industry within the country.
- (q) To receive, with the prior approval of the Central Government ,monetary assistance from foreign sources including international organizations for training programmes ,scientific research exchange programmes and for strengthening infrastructure.
- (r) To take over the present "National Tissue Culture Facility" fully funded by DBT, at the University of Poona, Pune with its present scientific and research activities and ancillary project grants and related research and infrastructural facilities.
- (s) To do all such other lawful acts and things either alone or in conjunction with other organizations or persons as the Facility may consider necessary, incidental or conducive to the above mentioned objectives or any of them.



A. SIGNIFICANT ACCOUNTING POLICIES

1) BASIS OF PREPARATION / ACCOUNTING CONVENTION :

The Financial Statements have been prepared in accordance with Indian Generally Accepted Accounting Principles (IGAAP) under the historical cost convention on the accrual basis, except where specified otherwise in case of significant uncertainties.

The Accounts are prepared as per the common format of accounts for all Autonomous Institute as per letter No. BT/MED/NCCS/ADMN/2002 dtd. June 10,2002 of Department of Biotechnology, New Delhi and Comptroller & Auditor General of India (CAG) letter No. OA-VII(MISC/CORRES/2002-03/1165)dtd.16 October 2002.

2) INVENTORY VALUATION :

Inventory is valued at lower of Cost or Net Realisable Value. The consumption of inventory including chemicals and consumables has been recognized as an expenditure at the time of booking of the purchase of inventory in the books of accounts. Hence, the inventory at the end of the financial year NIL.

3) REVENUE RECOGNITION

All Revenue items are accounted for on accrual basis of accounting except Guest House Receipts, Hostel fees, Ph. D. Fees and Bank Account Interest which are accounted on cash basis of accounting.

4) FIXED ASSETS :

Fixed assets are stated at cost of acquisition inclusive of inward freight, duties and taxes and incidental and direct expenses related to acquisition.

5) DEPRECIATION /AMORTIZATION:

Depreciation on Fixed Assets except Leasehold Premises has been provided on Written Down Value Method at the following rates which are calculated based on the useful life of each asset.

Depreciation is calculated at half of the rate calculated as above for the assets which are capitalized after September of the current financial year.

Depreciation on the Assets costing Rs. 5,000/- or less each are fully provided.

Lease hold Premises are amortized over the period of lease. The annual amortization expense for a leasehold land is the cost of the leasehold land divided by the lease term, assuming straight-line amortization.

| Sr.No. | Group of Asset | Rate of Depreciation |
|--------|----------------|----------------------|
| 1 | Building | 4.87% |
| 2 | Furniture | 25.89% |
| 3 | Library Books | 18.10% |
| 4 | Equipment | 18.10% |
| 5 | Vehicle | 39.30% |



6) GOVERNMENT GRANTS/SUBSIDIES :

- i) Where the Government Grants are in the nature of capital contribution, i.e., they are given with reference to the total or part investment or by way of contribution towards its total or part capital outlay, are recognized as "Contribution towards Capital Fund" under head "Corpus/Capital Fund".
- ii) Grants received towards recurring expenditure are treated as income under income & expenditure account.
- iii) Grants received from sponsoring agencies for specific Projects are recognized as "Earmarked Funds"
- iv) Government grants/ subsidy's are accounted on realization basis.
- v) Deduction from Grant-in aid Salary and Corpus Capital Fund represent unspent grant in the nature of Salary and Capital is written back through Treasury Single Account to the Government of India.

7) FOREIGN CURRENCY TRANSACTION:

Transactions denominated in foreign currency are accounted at the exchange rate prevailing at the date of the transaction.

8) RETIREMENT BENEFITS :

Provision for Liability towards gratuity payable on death / retirement of employees and leave encashment is not made due to implementation of "Treasury Single Account" because, under this system parking of funds by way of provision for Retirement Benefits is not permitted. The present fund balance represents accumulated fund upto FY 2020-21. Those will be utilized for retirement benefits settlement up to 2025-2026.

9) EARMARKED/ENDOWMENT FUNDS :

- i) As explained to us, Grants/Funds received from Sponsoring agencies for specific Projects are recognised as " Earmarked Funds". These Grants/Funds are credited to respective Project Funds as per the norms associated with these Projects.
- ii) The amounts represent at the year end of Rs. 18,75,77,275.21 are Unspent / and Rs. (3,72,89,698.57) (Overspent) grants and receivables in respect to Projects are subject to confirmation from the granting authorities, reconciliation and consequential adjustments, if any.
- iii) Since F.Y. 2002-2003 the aggregate accumulated cost upto F.Y. 2024-2025 of Rs. 93,02,22,099.78 for acquiring fixed assets of respective Projects.

Date: 24th June, 2025

Place: Pune


OFFICER 'C' ACCOUNTS
NCCS

वैभव आ. अरगडे
Vaibhav A. Argade
अधिकारी 'ग' (लेखा)
Officer "C" (Accounts)
रा.को.वि.के./NCCS Pune-411007


DIRECTOR (ADDL. CHARGE)
NCCS

निदेशक(अतिरिक्त प्रभार)
राष्ट्रीय कोशिका विज्ञान केन्द्र, पुणे
Director (Addl. Charge)
National Centre for Cell Science, Pune



FOR M/s. M S B S & COMPANY
CHARTERED ACCOUNTANTS
FIRM REG. NO. 136148W




NITIN MULIK
PARTNER

M.NO.165937

Date: 24th June,2025
Place: Pune
UDIN:25165937BMLZMF2606

SCH. "25" : CONTINGENT LIABILITIES AND NOTES ON ACCOUNTS FOR THE YEAR 2024-2025

1) CONTINGENT LIABILITIES

Taxation:- Inview of there being no taxable income under Income Tax Act 1961, No provision for Income Tax has been considered necessary.

| Assessment Year | Status of assessment (Pending / completed/ appeal filed) | Demand outstanding (in Rs. if any) | Remark |
|-----------------|---|------------------------------------|---|
| 2015-16 | Income Tax Dept. has preferred appeal with ITAT against the order of CIT (A) | -- | Hon'ble Bombay High Court has remanded back the case to Hon'ble ITAT, Pune |
| 2016-17 | Assessment Complete u/s 143(3). We have filed an appeal with CIT (A) Form 35 dt. 14.01.2019. | -- | Appeal pending at CIT appeal level. |
| 2017-18 | Assessment Complete u/s 143(3). Against which we have filed Appeal with CIT (A). Order of the same has been passed by CIT(A) dt 03/02/2021 which has quashed entire demand raised vide order u/s 143(3). Penalty Order under section 272A(1)(d) of the Income Tax Act, 1961 has been passed by Exemption Circle Pune dt 09/12/2019 for Noncompliance to notice u/s 142(1) dated 05-03-2019 | Nil* | CIT Appeals allowed the appeal and nullified the tax demand and Tax ascertained is Nil. |
| 2018-19 | Rectification rights with AST, Mar 18, 2020. Refund kept on hold, Intimation u/s 245 is issued proposing adjustment of refund towards outstanding demand Oct 1, 2019 Refund adjusted | -- | Intimation u/s 245 |
| 2019-20 | Processed with no demand/refund, Mar 20, 2021. Intimation u/s 143(1) is received from Income Tax Department. | -- | Intimation u/s 143(1) |
| 2021-22 | Notice u/s 143(1)(a) dated 01.07.2022 has been received proposing adjustment for non-allowance of exemption of Rs. 40,40,82,242/- u/s 10(21) of the IT Act, 1961 | Rs. 27,09,80,410/- | Order u/s 154. We have filed application for rectification and also Appeal filed which is pending at CIT appeal level. |



| | | | |
|---------|--|----|-----------------------|
| 2022-23 | Assessment Complete u/s 143(3). Returned income accepted as it is, Nil demand and ascertained refund of Rs. 90,500/- which is adjusted | -- | Intimation u/s 143(1) |
| 2023-24 | Intimation u/s 143(I) is received from Income Tax Department and ascertained refund of Rs. 198,110/- which is adjusted | -- | Intimation u/s 143(1) |
| 2024-25 | Intimation u/s 143(I) is received from Income Tax Department and ascertained refund of Rs. 110,860/- which is adjusted | -- | Intimation u/s 143(1) |

* CPC had raised demand of Rs. 1,42,86,178/- which is made NIL vide order dated 03.02.2021 & by CIT (Appeals)

In the above matters we are following up with Income Tax Department through our Consultant.

Contingent liabilities at the Traces for non/ short payment of TDS is of Rs. 1,51,630.

2) CAPITAL COMMITMENTS

Estimated value of contracts remaining to be executed on captial account and not provided for (net of advances) Rs. 26.31 cores (previous year Rs 38.23 Crores)

3) LEASE OBLIGATIONS

The land on which the NCCS complex is situated is owned by the State Government of Maharashtra. Agreement for the ground rent/ lease rent payable, if any, for the use of land is not entered into and no provision in respect of the same has been made in the books of accounts.

4) CURRENT ASSETS, LOANS & ADVANCES:

In the opinion of the management, current assets, loans, advances have value on realisation in the ordinary course of business, equal at least to the aggregate amount shown in the Balance Sheet.

5) BALANCE CONFIRMATION

The balances of all deposits payable and paid, sundry creditors, advance from customers are subject to confirmation and reconciliation, if any. The Trust is in the process of getting confirmation from all parties and the impact of which will be given in due course of reconciliation.

6) FIXED ASSETS PHYSICAL VERIFICATION

The Institute has maintained its fixed assets register and has also conducted physical verification of fixed assets which are capitalised during the current financial year, there are no discrepancies were found in the Register and Verification Report for the financial year 2024-25.

7) INTEREST EARNED ON GRANTS RECEIVED FROM DBT

Interest earned on Grants received towards Earmarked funds has also been credited to their respective project fund account.



8) TAXATION

In view of there being no taxable income under the Income Tax Act, 1961, no provision for Income Tax has been considered necessary.

9) FOREIGN CURRENCY TRANSACTIONS

i) Value of Import calculated on CIF Basis

| | Current Year | Previous Year |
|-----------------------------|--------------|---------------|
| Purchase of finished goods | 0.00 | 0.00 |
| Raw Material & Components | 0.00 | 0.00 |
| Capital Goods | 0.00 | 0.00 |
| Store, Spares & Consumables | 48.06 Lakhs | 30.78 Lakhs |

ii) Expenditure in Foreign Currency

| | | |
|---|------|------|
| Interest Payment to Bank/ Financials Institutions | 0.00 | 0.00 |
| Other Expenditure | 0.00 | 0.00 |
| - Service Purchase | 0.00 | 0.00 |
| - Others | 0.00 | 0.00 |

iii) Earning in Foreign Currency

| | | |
|------------------------------|------|------|
| FOB Value of Export of Goods | 0.00 | 0.00 |
| Export of Services | 0.00 | 0.00 |

10) PAYMENT TO AUDITORS

As an Auditor

| | | |
|---------------------|-------------|-------------|
| Audit Fees | 1,41,600.00 | 1,41,600.00 |
| Taxation Matters | 0.00 | 0.00 |
| Certifications | 0.00 | 0.00 |
| Management Services | 0.00 | 0.00 |
| Others | 8,000.00 | 8,000.00 |

11) Corresponding figures for the previous year have been re-grouped / re-arranged, wherever necessary.

12) All the schedules are annexed to and form as integral part of Balance Sheet as at 31st March, 2025 and the Income and Expenditure Account for the year ended on that date.

Date: 24th June, 2025

Place: Pune

FOR M/s. M S B S & COMPANY
CHARTERED ACCOUNTANTS
FIRM REG. NO. 136148W



OFFICER 'C' ACCOUNTS
NCCS

वैभव अ. अरगडे
Vaibhav A. Argade
अधिकारी 'ग' (लेखा)
Officer "C" (Accounts)
रा.को.वि.के./NCCS Pune-411007

DIRECTOR (ADDL. CHARGE)
NCCS

निदेशक(अतिरिक्त प्रभार)
राष्ट्रीय कोशिका विज्ञान केन्द्र, पुणे
Director (Addl. Charge)
National Centre for Cell Sciences, Pune




M/s. M S B S & Company
Chartered Accountants
PUNE
*
NITIN MULIK
PARTNER
M.NO.165937

Date: 24th June, 2025
Place: Pune
UDIN:25165937BMLZMF2606

NATIONAL CENTRE FOR CELL SCIENCE, PUNE - 411 007.

SCHEDULES FORMING PART OF INCOME AND EXPENDITURE ACCOUNTS FOR THE YEAR ENDED 31.03.2025

CONTINGENCIES BIFURCATION

| Particulars | 2024-25 | 2023-24 | Amount (Rs.) |
|---|-----------------------|-----------------------|--------------|
| Conti-Local Conveyance | 23,14,490.00 | 28,52,242.00 | |
| Conti-Advertisement and Publicity | 5,43,979.00 | 7,33,933.00 | |
| Conti-Vehicle Petrol Expenses | 1,20,598.00 | 71,707.00 | |
| Conti-Academic Recognition Fee | - | 7,37,625.00 | |
| Conti-Fees Registration& Membership Charges | 11,49,624.00 | 1,37,878.00 | |
| Conti-Honorarium | 10,72,883.00 | 10,92,112.00 | |
| Conti-Hospitality Expenses | 18,62,430.00 | 14,35,328.00 | |
| Conti-Laundry Expenses | 1,63,905.00 | 1,75,872.00 | |
| Conti-Meeting Expenses | - | 4,50,000.00 | |
| Conti-Membership Fees and Subscriptions | 3,51,851.00 | 4,02,333.00 | |
| Conti-Miscellaneous Purchase | 28,26,491.00 | 22,07,148.00 | |
| Conti-Miscellaneous Expenses | 4,01,305.00 | 12,56,507.20 | |
| Conti-Postage and Telephone | 18,35,092.00 | 13,85,355.00 | |
| Conti-Printing and Stationery | 11,41,962.24 | 1,28,860.00 | |
| Conti-Professional & Legal Charges | 50,88,526.00 | 30,34,564.00 | |
| Conti-Repairs and Maintenance | 66,87,813.00 | 42,83,911.00 | |
| Conti-Repairs and Maintenance- Contract | 94,56,108.00 | 78,72,321.00 | |
| Conti-Seminar / Symposia | 13,10,878.00 | 9,62,033.00 | |
| Conti-Vehicle Insurance | 10,262.00 | 10,127.00 | |
| Conti-Day Care expenses | 37,604.00 | 34,022.00 | |
| Grand Total | 3,63,75,801.24 | 2,92,63,878.20 | |

